Entries |
Document | Title | Date |
20080206800 | Method for Measuring Tyrosine Kinase Phosphorylation - Method, kit and composition for measuring the autophosphorylation of one or more tyrosine kinases in presence of a kinase inhibitor compared to the absence of said kinase inhibitor for kinase specificity profiling of kinase inhibitors. | 08-28-2008 |
20080213810 | Screening Method for Hiv Rt Inhibitors - The present invention is directed to methods for identifying a specific class of inhibitors of HIV reverse transcriptase that act differently from known reverse transcriptase inhibitors. In particular, the invention is based on identifying inhibitors which have higher inhibitory activity in presence of a nucleoside triphosphate or pyrophosphate. | 09-04-2008 |
20080213811 | SENSOR PROTEINS AND ASSAY METHODS - The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays. | 09-04-2008 |
20080213812 | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression - Methods and compositions are provided for modulating, e.g., increasing or decreasing, the expression of telomerase reverse transcriptase (TERT). In the subject methods, the binding interaction of the TERT Site C repressor site with a Site C repressor protein complex made up of one or more proteins is modulated to achieve the desired change in TERT expression. A feature of the subject invention is that the target Site C repressor protein complex includes an LSF protein. The subject methods and compositions find use in a variety of different applications, including the immortalization of cells, the production of reagents for use in life science research, therapeutic applications; therapeutic agent screening applications; and the like. | 09-04-2008 |
20080220462 | KIT FOR DETECTION OF HEMOLYTIC STREPTOCOCCUS - A reagent is provided for the detection of an exotoxin protein produced by a beta-hemolytic streptococcus bacteria suspected of being present in a host biological fluid collected from a subject. An enzyme inhibitor is present to inhibit rogue protein modification of the substrate to prevent a false positive result of the color change. A kit is provided that is readily usable by an untrained user and merely requires that an element of the kit be contacted with a biological sample and thereafter no further actions are required by the user before a discernable color change is observed with visible or UV light and a positive/negative results reference card. | 09-11-2008 |
20080227131 | Signalling Assay and Cell Line - The invention relates to a sensor for indicating the transduction and inhibition of stress signals through the p38-MAPK pathway in living cells. The sensor comprises a reporter gene product and an isoform of p38 Mitogen Activated Protein Kinase (MAPK). The invention also provides plasmid and viral vectors containing nucleic acids encoding the sensor for the transfection of living cells. Stable cell lines expressing the sensor can be used in a live-cell or fixed-cell assay to measure activation or modulation of the pathway. | 09-18-2008 |
20080233602 | Detecting and profiling molecular complexes - Methods are provided for detecting the formation of complexes of molecules, especially proteins, in a sample, such as a cell or tissue lysate. In one aspect, a cleaving probe specific for a first protein in a complex and one or more binding compounds specific for one or more second proteins in a complex are provided. Upon binding, the cleaving probe is induced to generate an active species, such as singlet oxygen, that cleaves molecular tags attached to the binding compounds only in the local region of the cleaving probe. The released molecular tags are separated from the assay mixture and from one another to provide a readout that is related to the number and types of proteins present in the complex. | 09-25-2008 |
20080233603 | Fluorine NMR spectroscopy for biochemical screening - High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF | 09-25-2008 |
20080261255 | Proteins, Sensors, and Methods of Characterizing Analytes Using the Same - A protein sensing molecule is capable of binding an analyte in a sample. The protein sensing molecule includes a first detectable quality that changes in a concentration dependent manner when the protein sensing molecule is bound to the analyte. The protein sensing molecule also includes a second detectable quality that does not undergo substantial change when the protein sensing molecule is bound to the analyte. The protein sensing molecule may be used in methods for characterizing samples and may also be used in sensors. | 10-23-2008 |
20080261256 | Methods of assaying receptor activity and constructs useful in such methods - Described are methods of detecting G-protein coupled receptor (GPCR) activity in vivo and in vitro; methods of assaying GPCR activity; and methods of screening for GPCR ligands, G protein-coupled receptor kinase (GRK) activity, and compounds that interact with components of the GPCR regulatory process. Constructs useful in such methods are described. | 10-23-2008 |
20080274486 | Method of Assaying Fad Synthetase - The present invention relates to methods of determining activity of flavin adenine dinucleotide (FAD) synthetase, and methods of identifying compounds that modulate the activity of this enzyme. | 11-06-2008 |
20080274487 | Use of Serum/Glucocorticoid-Regulated Kinase - The invention relates to the use of an SGK protein, a functional derivative or fragment thereof, or a nucleic acid coding for one such protein, fragment or derivative, in order to discover active ingredients for the prevention or treatment of degenerative cartilage changes. | 11-06-2008 |
20080280313 | Coccidian Parasite Casein Kinase I as a Chemotherapeutic Target for Antiprotozoal Agents - Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the species | 11-13-2008 |
20080280314 | Devices and methods for profiling enzyme substrates - The present invention relates to apparatus and methods for separating and detecting enzyme substrates using separation gels. For example, the apparatus and methods can be used to separate and detect kinase substrates for further analysis. The apparatus and methods can also be used to detect enzyme inhibitors, such as kinase inhibitors. | 11-13-2008 |
20080299594 | Proteomic analysis of biological fluids - The invention concerns the identification of proteomes of biological fluids and their use in determining the state of maternal/fetal conditions, including maternal conditions of fetal origin, chromosomal aneuploidies, and fetal diseases associated with fetal growth and maturation. In particular, the invention concerns the identification of the proteome of amniotic fluid (multiple proteins representing the composition of amniotic fluid) and the correlation of characteristic changes in the normal proteome with various pathologic maternal/fetal conditions, such as intra-amniotic infection, or chromosomal defects. | 12-04-2008 |
20080305507 | METHODS AND COMPOSITIONS FOR ASSAYING HOMOCYSTEINE - This invention relates generally to the field of homocysteine detection. In particular, the invention provides a method for determining homocysteine presence or concentration in samples, which method comprises: contacting a sample containing or suspected of containing Hcy with a Hcy co-substrate and a Hcy converting enzyme in a Hcy conversion reaction to form a Hcy conversion product and a Hcy co-substrate conversion product; and assessing the Hcy co-substrate conversion product to determine the presence, absence and/or amount of the Hcy in the sample. The Hcy co-substrate conversion product may be assessed directly, or it may be assessed by further conversion of the Hcy co-substrate conversion product into another material by the action of one or more additional enzymes. A kit for assaying homocysteine based on the same principle is also provided. | 12-11-2008 |
20080318262 | Protein Cleavage at Aspartic Acid Using Chemical Reagents - The present invention relates to the methods of identifying and quantifying polypeptides in a given sample by mass spectrometric analysis. More specifically, the invention provides the methods for sample preparation for proteomic analysis: the methods for the fragmentation of proteins into peptides with the specific cleavage rule (cleavage at amino-terminal or carboxyl-terminal of aspartic acid), which are suitable for the analysis by mass spectrometry apparatus. | 12-25-2008 |
20080318263 | METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION - An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma. | 12-25-2008 |
20080318264 | Biomarkers Associated With Age-Related Macular Degeneration - The invention relates to proteins associated with age-related macular degeneration (AMD). These proteins, which are present in blood, are expressed in individuals with AMD at either elevated or reduced levels compared to healthy individuals. The invention provides methods for diagnosing AMD. The invention provides methods for assessing the efficacy of treatment of AMD. The invention provides methods for monitoring the progression of AMD. | 12-25-2008 |
20090004683 | Indicator Agent for Noninflammatory Stress Response and Use Thereof - A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent. | 01-01-2009 |
20090023168 | Method of screening placental proteins responsible for pathophysiology of preeclampsia, and marker for early diagnosis and prediction of preeclampsia - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas. | 01-22-2009 |
20090023169 | High throughput sarcomeric assay - The present invention provides high throughput screening systems for identifying compounds that modulate the biological activity of a biochemically functional sarcomere. The method can be performed in plurality simultaneously with fluorescence or absorbance readouts. | 01-22-2009 |
20090029399 | METHOD FOR RAPID DETERMINATION OF THIOPURINE METHYLTRANSFERASE ACTIVITY - This document provides methods and materials related to rapid, quantitative determination of TPMT activity in biological samples. Also featured are compositions and kits useful for determination of TPMT activity in biological samples. | 01-29-2009 |
20090035796 | Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof - Sensors for detecting enzyme activity are provided. The sensors include substrate modules having environmentally sensitive labels and detection modules whose binding to the substrate modules results in changes in signals from the environmentally sensitive labels or polypeptides or polypeptide substrates including environmentally sensitive or fluorescent labels. Compositions including substrate modules, polypeptides, or polypeptide substrates and nucleic acids encoding enzymes and/or detection modules are also described. Methods of assaying enzyme activity using sensors including environmentally sensitive or fluorescent labels are provided, as are related methods for screening for modulators of enzyme activity. | 02-05-2009 |
20090047694 | Clinical Intervention Directed Diagnostic Methods - The invention provides methods for assessing the clinical status of a patient. In particular, the invention provides methods for identifying the presence of or likelihood of disease or disease recurrence. In practice, methods of the invention provide the ability to screen patients into one of three distinct clinical categories. Based upon measurement of clinically-relevant biomarkers in a sample obtained from a patient, the invention allows the unambiguous identification of patients who are not at risk for or do not have the relevant disease, the unambiguous identification of patients at increased risk or who have the disease; and the identification of patients who should receive standard of care treatment and/or monitoring. Use of the invention maximizes the number of patients who will receive accelerated intervention or monitoring and minimizes those patients who will receive unnecessary standard of care or accelerated intervention or monitoring. | 02-19-2009 |
20090047695 | MICRODEVICES FOR HIGH-THROUGHPUT SCREENING OF BIOMOLECULES - Methods and devices for the parallel, in vitro screening of biomolecular activity using miniaturized microfabricated devices are provided. The biomolecules that can be immobilized on the surface of the devices of the present invention include proteins, polypeptides, nucleic acids, polysaccharides, phospholipids, and related unnatural polymers of biological relevance. These devices are useful in high-throughput drug screening and clinical diagnostics and are preferably used for the parallel screening of families of related proteins. | 02-19-2009 |
20090047696 | DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP | 02-19-2009 |
20090061469 | Methods and kits for assaying acetyl transferase or deacetylase activity - The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enzymatically acetylated or deacetylated. | 03-05-2009 |
20090068693 | HIGH SENSITIVITY ASSAY FOR DETECTION OF NUCLEOSIDE DIPHOSPHATE PRODUCTION - The present invention provides assays for detecting ADP, GDP and inorganic phosphate. These assays can be used directly to detect the presence of ADP, GDP and inorganic phosphate or can be used as part of a number of methods for identifying candidate agents that bind to a target protein or serve as modulators of the biological activity of a target protein. | 03-12-2009 |
20090068694 | Enzyme Activity Measurements Using Bio-Layer Interferometry - Disclosed are enzyme assays using biolayer interferometry. Assays may be carried out using immobilized substrate or with a substrate capture format. In certain embodiments, the assays are carried out using unlabeled substrates. The methods are broadly applicable to enzyme assay measurements, can be carried out in vivo or in vitro, and are easily multiplexed. | 03-12-2009 |
20090075311 | ASSESSING COLORECTAL CANCER BY MEASURING HEMOGLOBIN AND M2-PK IN A STOOL SAMPLE - The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is, for example, practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of hemoglobin and M2-PK and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer in a method of this invention the level of one or more additional marker may be determined together with hemoglobin and M2-PK in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising hemoglobin and M2-PK in the early diagnosis of colorectal cancer, and it teaches a kit for performing the method of the invention. | 03-19-2009 |
20090075312 | ASSESSING COLORECTAL CANCER BY MEASURING OSTEOPONTIN AND CARCINOEMBRYONIC ANTIGEN - The present invention relates to a method aiding in the assessment of colorectal cancer (=CRC). It discloses the use of a marker combination comprising osteopontin and carcinoembryonic antigen in the assessment of colorectal cancer. Furthermore, it especially relates to a method for assessing colorectal cancer from a liquid sample, derived from an individual by measuring at least the markers osteopontin and carcinoembryonic antigen in said sample. The marker combination comprising osteopontin and carcinoembryonic antigen can, e.g., be used in the early detection of colorectal cancer or in the surveillance of patients who undergo therapy, e.g., surgery. | 03-19-2009 |
20090075313 | Split protein fragments, split protein systems, methods of making split protein systems, and methods of using split protein systems - Split protein herpes simplex virus type 1 thymidine kinase [HSV1-TK or TK] TK fragments, split protein TK systems, methods of imaging protein-protein interactions, methods of cellular localization of proteins, methods of evaluating protein translocation and trafficking, and the like, are provided. In addition, the present disclosure includes compositions used in and methods relating to non-invasive imaging (e.g., positron emission tomography (PET) imaging) in vivo and in vitro. | 03-19-2009 |
20090093006 | Core 2 Beta(1,6)-Acetylglycosaminyltransferase as Diagnostic Marker for Atherosclerosis - A method of indicating the presence of the atherosclerosis (particularly coronary artery atherosclerosis) in a subject is provided, comprising comparing the level of Core 2 GlcNAc-T in a tissue sample from a subject with a reference level determined for the same tissue. A level of Core 2 GlcNAc-T in the tissue sample from a subject that is higher than that of the reference level being indicative that the subject is afflicted with atherosclerosis (particularly coronary artery atherosclerosis—coronary artery disease—CAD). In preferred embodiments, the sample consists of leukocytes and the protein level is determined as the enzymatic activity using radiolabeled UDP-GlcNAc and a Galβ(1,3)-GalNAc derivative. | 04-09-2009 |
20090104638 | Methods for Building Atomic Models of Protein Molecules and Determining Drug Candidates Using MGST1 - Methods for building an atomic model of a protein molecule comprising: (a) identifying a protein molecule with at least 20% sequence identity with Microsomal Glutathione Transferase 1 (MGST1) and (b) utilizing the atomic coordinates of MGST1 to obtain an atomic model of the identified protein molecule and methods for determining a drug candidate compound that interacts with members of the MAPEG superfamily, in particular MGST1 are also provided. | 04-23-2009 |
20090111133 | Gel Filtration Standard - A gel filtration standard suitable for use as molecular weight markers for gel filtration chromatography for a mobile phase with denaturant. In one embodiment, the gel filtration standard comprises ovalbumin, myoglobin, and vitamin B | 04-30-2009 |
20090111134 | Multiplex PCR Assay For Identification of USA300 and USA400 Community-Associated Methicillin Resistant Staphylococcal Aureus Strains - The present invention relates to multiplex polymerase chain reaction (PCR) assays for | 04-30-2009 |
20090111135 | METHOD AND APPARATUS FOR DIAGNOSES OF HEMANGIOSARCOMA IN MAMMALS - The disclosure relates to a method for detecting hemangiosarcoma in canines. The method includes the steps of: (1) obtaining a quantity of blood from the subject canine; (2) separating the quantity of blood into a serum portion and a non-serum portion; (3) contacting the serum portion of the blood with a detector to detect presence of an amount of Thymidine Kinase (TK); and (4) detecting the level of TK in serum and determining whether TK is present in amounts of about 8 units/mL or greater. | 04-30-2009 |
20090111136 | METHOD FOR DETECTION, DETERMINATION OR PREDICTION OF HEPATIC DISORDER - The invention relates to a method for examining a hepatic disorder (e.g., NASH), which is less invasive and highly sensitive and which can be performed in a simple manner. According to the method, the level of a mitochondrion-derived protein (e.g., ornithine carbamoyltransferase or glutamate dehydrogenase) of a blood sample from a patient suffering metabolic syndrome and/or non-alcoholic fatty liver disease is measured, and the measured protein level is compared with an averaged value of protein levels of healthy volunteers, whereby whether or not the patient has a hepatic disorder (e.g., NASH) is determined. | 04-30-2009 |
20090111137 | SIMULTANEOUS DETECTION OF METABOLIC ENZYME ACTIVITY AND METABOLITE LEVELS - Provided are methods for detecting a metabolic disorder in an individual using mass spectrometry. One method involves (a) contacting a sample containing (i) one or more metabolically indicative enzymes and (ii) one or more metabolic analytes, with one or more substrates for said one or more enzymes to produce a reaction admixture, under conditions wherein at least one of said enzymes is capable of acting on a corresponding substrate to generate at least one product, and wherein one or more protease inhibitors are present; (b) contacting said reaction admixture with a reagent that inhibits the ability of said one or more enzymes to act on a corresponding substrate, wherein said one or more metabolic analytes and said at least one product are soluble in said reagent; to produce a test sample and (c) determining the presence or amount of said one or more metabolic analytes and said at least one product contained in said test sample using mass spectrometry, wherein a determined presence or amount of said one or more metabolic analytes and said at least one product correlates with presence or absence of said metabolic disorder product correlates with presence or absence of said metabolic disorder. | 04-30-2009 |
20090117598 | Method for identifying compounds that affect a transport of a protein through a membrane trafficking pathway - The present invention relates to a method for identifying compounds that affect a transport of a receptor of interest through a specific membrane trafficking pathway mediated by said receptor within the context of a generic membrane trafficking pathway, which generic pathway is not mediated by said receptor, characterised by the following steps:
| 05-07-2009 |
20090117599 | METHOD OF DETECTING SUGAR CHAINS HAVING GlcNAc TRANSFERRED BY GnT-V - It is intended to provide a method by which sugar chains having GlcNAc transferred by GnT-V can be accurately detected, screened and purified. In this detection method, two kinds of lectins differing in detailed GlcNAc-specificity are used together. As shown in FIG. | 05-07-2009 |
20090136976 | Luminescence-based composition - Luminescence-based compositions for measurement of aspartate aminotranserase, alanine aminotransferase, total-bilirubin, creatinine phosphokinase, or lactate dehydrogenase, wherein the chemiluminescence-based composition comprises 0.01-100 mM of luminol, 0.001-1000 U/mL of horseradish peroxidase (HRP), 0-10% of Triton X-100, 0-100 mM PIP, and 5˜500 mM of buffer at pH 6˜9, and the luminescence-base composition measures Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or lactate dehydrogenase (LDH). | 05-28-2009 |
20090136977 | NOVEL TARGETS FOR ALZHEIMER'S DISEASE - Compositions and methods for post-translational modifications that include acetylCoA:lysine acetyltransferase activity in the ER lumen are provided. The disclosed compositions and methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's. | 05-28-2009 |
20090136978 | METHOD FOR MEASURING PHOSPHORIC ACID - In measuring phosphoric acid by the use of an enzyme cycling system using a dehydrogenase together with a thio-NADP, a thio-NAD, a reduced thio-NADP or a reduced thio-NAD as a coenzyme, phosphoric acid is measurable in a wide concentration range from a low concentration to a high concentration by measuring phosphoric acid after previous removal of free phosphoric acid in reagent components for the measurement. | 05-28-2009 |
20090142784 | METHODS - A method for identifying a compound expected to be useful in modulating a LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates the protein kinase activity of a LRRK2 polypeptide on a substrate Ezrin/Radixin/moesin (ERM) family polypeptide and (2) selecting a compound which modulates the LRRK2 polypeptide protein kinase activity. Such a compound may be useful in treating Parkinson's Disease or Parkinsonism. A catalytically active fragment of LRRK2 is identified, requiring the GTPase, COR and kinase domains as well as the WD_40-like motif and C-terminal tail. | 06-04-2009 |
20090142785 | Capturing carrier, capturing device, analysis system using the same, and method for capturing and testing microorganisms - In order to make a process of capturing and testing air-borne microorganisms more convenient and quick, a capturing device which comprises the capturing carrier comprising a polymer which is in a gel phase at the time of capturing the microorganisms but undergoes a phase transition under heating to a sol phase at the temperature at or less than 40° C. (especially in the temperature range between 15° C. and 37° C.), and a vessel to contain the capturing carrier is used. Further, by comprising a test reagent in the polymer, the test reagent can be eluted upon said phase transition from a gel phase to a sol phase. By heating the capturing carrier, a phase transition to a sol phase can occur at or less than 40° C. As such, since recovery of microorganisms and addition of a test reagent to the microorganisms can be carried out simultaneously, the process can be simplified and the process time can be shortened. | 06-04-2009 |
20090148876 | METHODS FOR THE GENERATION OF CARTILAGE-LIKE MATERIAL BY MECHANICAL LOADING - A cartilage-like biomaterial is bioengineered by using a self-aggregating suspension cell culture with hydrostatic mechanical force without the use of a scaffold or foreign matrix for cell attachment during culture. The cells in suspension culture may be preconditioned prior to application of the hydrostatic mechanical force, such as hydrostatic pressure, for a period of time in the range of about 1 week to about 10 weeks. The cartilage-like biomaterial shares critical structural, phenotype, and functional characteristics with native, intact cartilage tissue. | 06-11-2009 |
20090155827 | PIGF and FLT-1 as Prognostic Parameters for Cardiovascular Diseases - The present invention refers to a use of an ex vivo method comprising the determination of PlGF and sFlt-1 in a sample for diagnosis, risk stratification and/or monitoring of a vascular disease with atherosclerotic etiology, in particular a coronary heart disease such a unstable angina pectoris or myocardial infarction, and/or for estimation of the probability of developing such a disease, as well as for identification of a patient supposed to benefit from a therapy by agents reducing the risk for a cardiovascular disease. In the method (i) a ratio of [PlGF=high:sFlt-1=low], and/or (ii) a PlGF concentration in the upper two tertiles of a reference collective, and an sFlt-1 concentration in the lower tertile of the reference collective, and/or (iii) a PlGF result above a PlGF reference value, and an sFlt-1 result below an sFlt-1-reference value indicate an elevated probability for an adverse event. The present invention also refers to the used method. The present invention further refers to a diagnostic kit and its use as well as to an assay element and its use. | 06-18-2009 |
20090155828 | METHODS OF DETECTING PROSTATE CANCER - Proteins specific for prostate epithelial cells, normal or neoplastic, are identified and used for diagnosis, development of antibodies, and for evaluating drugs that react with the neoplastic specific proteins. Affinity based probes are used that react specifically with the active site to provide a measure of the enzyme activity of the cells. Prostate epithelial neoplastic cells can be used in screening candidate drugs for their effect in changing the proteome profile as to the serine-threonine hydrolase enzymes, using the affinity based probes for determining the profile. | 06-18-2009 |
20090162881 | METHOD OF MEASURING ADENINE NUCLEOTIDE - A high sensitivity electrochemistry type method for measuring adenine nucleotide which has a convenient and further miniaturized measuring device structure; is low in consumptive power; and does not require a treatment operation for substances that cause turbidity is provided. A method for measuring adenine nucleotide, which comprises a step A for converting adenosine triphosphate to adenosine diphosphate by an enzyme E | 06-25-2009 |
20090170141 | GHRELIN O-ACYLTRANSFERASE (GOAT) BIOCHEMICAL ASSAY - Ghrelin is acylated ghrelin O-acyltransferase. Ghrelin O-acyltransferase assays comprise contacting a mixture of ghrelin and recombinant ghrelin O-acyltransferase with an agent; and detecting a resultant decrease in acylation of the ghrelin by the acyltransferase. | 07-02-2009 |
20090170142 | USE OF 4'-PHOSPHOPANTETHEINYL TRANSFERASE AS A TARGET FOR IDENTIFYING ANTIBIOTIC MOLECULES - The present invention pertains to the use of a PptT protein, as a target for screening compounds for identifying those having an antibiotic activity, especially against a pathogenic bacterium containing mycolic acids. The invention also concerns an in vitro screening process for identifying compounds having an antibiotic activity, by measuring the activity of a PptT protein in the presence or absence of said compounds. | 07-02-2009 |
20090176263 | Canis sphingosine 1-phosphate receptort isoform 1 | 07-09-2009 |
20090176264 | Calibrator/Control for Simultaneous Assay of Proteins Capable of Complexing With One Another - Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest. | 07-09-2009 |
20090181414 | RETENTATE CHROMATOGRAPHY AND PROTEIN CHIP ARRAYS WITH APPLICATIONS IN BIOLOGY AND MEDICINE - This invention provides methods of retentate chromatography for resolving analytes in a sample. The methods involve adsorbing the analytes to a substrate under a plurality of different selectivity conditions, and detecting the analytes retained on the substrate by desorption spectrometry. The methods are useful in biology and medicine, including clinical diagnostics and drug discovery. | 07-16-2009 |
20090181415 | PREDICTION OF GENOTOXICITY - The likelihood that a compound will exhibit genotoxicity in a micronucleus test is predicted by the ability of the compound to inhibit a plurality of kinases from a selected group. | 07-16-2009 |
20090191578 | Canis sphingosine 1-phosphate receptor isoform 5 - A Canis sphingosine-1-phosphate (S1P) receptor isoform 5 (cS1P | 07-30-2009 |
20090208990 | HUMAN PROTEIN ACYL TRANSFERASES AND METHODS OF USES THEREFOR - The present invention provides the identification of human Ras palmitoyl acyl transfersase complexes, and nucleic acids coding therefor. In addition, methods of screening for modulators of human Ras palmitoyl acyl transfersase, including high throughput yeast screens, are also provided. | 08-20-2009 |
20090208991 | Prediction of bone marrow toxicity - The likelihood that a compound will exhibit bone marrow toxicity in an in vivo assay predicted by the ability of the compound to inhibit at least eight kinases from a selected group. | 08-20-2009 |
20090215098 | QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY - The disclosure relates to methods of quantitatively analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Isotopically labeled standards are employed. Purified enzymes and enzymes from crude cell lysates may be analyzed using the disclosed methods. As little as 0.02 pg of cell lysate may be detected. Also disclosed are kits for providing compositions so as to practice the disclosed methods. | 08-27-2009 |
20090215099 | METHOD OF IDENTIFYING CANCER BIOMARKERS AND CANCER PROGRESSION - An efficient method for identifying important cancer biomarkers and identifying progression of bladder cancer using pro-u-PA as a clinical tool is provided. Searching for biomarkers critical for bladder carcinoma diagnosis and prognosis, secreted proteomes of highly malignant U1 and pre-malignant U4 cell lines are first analyzed. Proteins in the cultured media of the U1 and U4 cell-lines were systematically examined by SDS-PAGE combined with MALDI-TOF mass spectrometry. Expression of pro-u-plasminogen activator (pro-u-PA) was confirmed by Western blot analysis and further evaluated. A statistically significant relationship between the low level and absence of pro-u-PA in urine with high stages and grades of the tumor samples was established. Constitutive expression of Ras dominant negative protein led to increased expression of pro-u-PA in cultured media, indicating the loss of pro-u-PA is associated with oncogenic transformation. The loss of pro-u-PA in urine has been identified as a marker of more advanced bladder carcinoma. | 08-27-2009 |
20090246809 | METHOD OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE, AND A DEVICE OF SUPPORTING A DIAGNOSIS OF A RISK OF CANCER RECURRENCE - A method of supporting a diagnosis of a risk of cancer recurrence is disclosed. The method provides a new determining value a recurrence risk score (RRS) which is calculated based on expression levels and activity values of two cyclin dependent kinases (CDKs). The risk of cancer recurrence is judged by comparing the RRS with a predetermined threshold level for RRS. | 10-01-2009 |
20090246810 | Use of MRP 8/14 levels for discrimination of individuals at risk of acute coronary syndromes - The present invention relates to a method for determining the risk whether an individual showing at least one symptom of an evolving acute coronary syndrome (ACS) is suffering from an acute coronary syndrome comprising the steps of (a) measuring, preferably in vitro, the level of MRP 8/14, wherein (b) if the level of MRP 8/14 is at least increased, then the individual is at risk of suffering from an acute coronary syndrome. The invention further relates to methods for ruling out whether an individual showing at least one symptom of an evolving ACS is suffering from an ACS, for assessing whether an individual showing at least one symptom of an evolving ACS is not at risk of suffering from an ACS and to discriminate if an individual showing at least one symptom of an evolving ACS is at risk to suffer from an ACS and or has no ACS. | 10-01-2009 |
20090253156 | MASS SPECTROMETRY METHODS FOR MULTIPLEXED QUANTIFICATION OF PROTEIN KINASES AND PHOSPHATASES - The inventions relates to methods and kits for capture and/or analysis of kinases and/or phosphatases in one or more samples. In some embodiments, a kinase inhibitor, e.g. staurosporine or its derivative, is used to capture kinases from a sample. In some embodiments, a phosphatase inhibitor, e.g. microcystin or its derivative, is used to capture phosphatases from a sample. Methods for quantitative analysis of captured kinases and/or proteases are also provided. In some embodiments, quantitative analysis is accomplished using mass spectrometry. In addition, the invention provides kits related to same. | 10-08-2009 |
20090253157 | METHOD OF DIRECTED DIFFERENTIATION OF PORCINE EMBRYONIC STEM CELLS AND USING THE SAID CELLS IN DRUG SCREENING - The present invention relates to a method of directed differentiation of porcine embryonic stem cells into specific neural lineages. The present invention also relates to a method for identifying neurogenic stimulator using the said porcine embryonic stem cells. | 10-08-2009 |
20090263841 | USE OF NNMT AS A MARKER FOR LUNG CANCER - The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer. | 10-22-2009 |
20090286269 | Method for detecting PrP using at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand - A method for detecting PrP in a biological human or animal sample that may contain said PrP. The method is characterized in that it uses a molecule containing at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand selected from macrocyclic ligands and glycosaminoglycans. | 11-19-2009 |
20090298105 | RECONSTITUTED HISTONE METHYLTRANSFERASE COMPLEX AND METHODS OF IDENTIFYI NG MODULATORS THEREOF - The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided. | 12-03-2009 |
20090305318 | Diagnostic Tests of Substance Use Disorders - The present invention relates to compositions and methods for identifying and quantifying platelet proteins. As certain behaviors and medical conditions alter the quantity of various platelet membrane proteins, the tools of the present invention are suitable for identification of biomarkers of these bodily states. For instance, the present invention provides methods and compositions for determining whether an individual is using alcohol or other licit or illicit drugs at levels hazardous or harmful to their health. The invention also provides methods for identifying individuals who would benefit from or who may be harmed by specific medications or therapies. | 12-10-2009 |
20090311731 | Modified Molecule - We describe a microbial cell, typically a bacterial cell, genetically engineered to produce a modified sugar nucleotide, for example UDP glucuronic acid, and the use of the modified sugar to transfer glucuronic acid to small acceptor molecules. | 12-17-2009 |
20090317849 | BIOCHIP FOR THE DETECTION OF PHOSPHORYLATION AND THE DETECTION METHOD USING THE SAME - The present invention relates to a biochip for the detection of phosphorylation and a detection method of phosphorylation using the same, more precisely a biochip prepared by integrating a recombinant fusion protein produced from the reaction of a kinase matrix selected from the group consisting of PKC (Protein Kinase C), cc2-PK (cdc2 Protein Kinase) and DNA-PK (DNA-dependent Protein Kinase) and the elevated protein Selenomonas ruminantium membrane protein on a substrate coated with an active group, a detection kit of phosphorylation composed of the said biochip and a cofactor labeled with a radio-isotope and a detection method of phosphorylation using the same. The biochip for the detection of phosphorylation of the present invention using a radio-isotope facilitates the detection of phosphorylation with a minimum amount of a sample by simple processes, compared with the conventional method using an antibody. Since this method can analyze a large amount of samples in a shorter period of time, it can be effectively used for the analysis of kinase activity. | 12-24-2009 |
20090317850 | Crystal Structure of Human 70KD Ribosomal Protein S6 Kinase 1 Kinase Domain - Crystallization of the 70 kDa ribosomal protein S6 kinase polypeptide 1 (p70S6K1) kinase domain for X-ray crystallography analysis to generate the three-dimensional structure of the p70S6K1 kinase domain is described. Further described is the use of the three 5 dimensional structure of p70S6K1 kinase domain for identifying and designing ligands or low molecular weight molecules that specifically bind to and modulate (inhibit) the kinase activity of p70S6K1. These ligands or molecules can be used for the treatment of metabolic disorders such as diabetes and for the treatment of various cancers. | 12-24-2009 |
20100009397 | SUBSTRATE-MIMETIC AKT INHIBITOR - Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors. | 01-14-2010 |
20100015650 | KINASE SUBSTRATES - Tyrosine kinase substrates are described herein that are phosphorylated by many and diverse tyrosine kinases, and are chemically stable relative to co-polymers of poly-EY or poly-EAY having random molecular weights in the range of 20-50 kDa. Tyrosine kinase substrate peptides are provided according to embodiments described herein which include an isolated tyrosine kinase substrate peptide having molecular weight in the range of about 0.5 kD-10 kD. Tyrosine kinase substrate peptides are provided according to embodiments described herein having no more than 50 amino acids. The peptides include 2-25 phosphorylation modules and each phosphorylation module has 2-3 amino acid residues. | 01-21-2010 |
20100021949 | Method for Detecting Transferase Enzymatic Activity - Methods and kits for detecting transferase activity in a sample by measuring ATP using a composition comprising an ATP-dependent bioluminescence-generating enzyme, a luminogenic molecule and one or more transferase quenching agents. | 01-28-2010 |
20100028921 | RISK STRATIFICATION FOR ACUTE CORONARY SYNDROME BY MEANS OF FRAGMENTS/PARTIAL PEPTIDES OF PROVASOPRESSIN, ESPECIALLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis. | 02-04-2010 |
20100028922 | IDENTIFICATION AND CHARACTERIZATION OF HCV REPLICON VARIANTS WITH REDUCED SUSCEPTIBILITY TO BENZOFURANS, AND METHODS RELATED THERETO - The present invention provides methods of decreasing the frequency of emergence, decreasing the level of resistance, and delaying the emergence of a treatment-resistant Hepatitis C viral infection, by administering to a subject, either in combination or in series, an inhibitor of the Hepatitis C RNA-dependent RNA polymerase NS5B, e.g., a benzofuran, such as 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide (HCV-796), and at least one additional anti-Hepatitis C agent, e.g., a ribavirin product or an immunomodulator, such as an interferon product. Additionally, the invention relates to methods of monitoring the course of treatment of a Hepatitis C viral infection, methods of monitoring and prognosing a Hepatitis C viral infection, and methods of identifying an individual with a decreased likelihood of responding to an anti-Hepatitis C viral therapy. These methods use the sequence and/or structure of the Hepatitis C RNA-dependent RNA polymerase NS5B to identify the emergence of a treatment-resistant Hepatitis C viral infection, particularly a benzofuran (e.g., HCV-796) treatment-resistant Hepatitis C viral infection. | 02-04-2010 |
20100035289 | DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. | 02-11-2010 |
20100041085 | Methods and kits for assaying acetyl transferase or deacetylase activity - The invention provides methods and kits for characterizing the activity of an acetyl transferase or deacetylase. The method involves enzymatically acetylating or deacetylating in vitro a substrate that is a peptide fragment of a full-length polypeptide, and then non-enzymatically acylating the peptide substrate with acyl groups that differ in molecular weight from the enzymatically added or removed acetyl groups. Typically, deuterated acetic anhydride is used to non-enzymatically acylate the substrate. The fully acylated substrate is then characterized by mass spectrometry to determine the amino acid positions of the substrate that are enyzmatically acetylated or deacetylated. | 02-18-2010 |
20100047835 | DIAGNOSIS OF INFECTIONS OR INFLAMMATORY DISEASES OF THE AIRWAYS AND LUNGS ASSOCIATED WITH HEART FAILURE - The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method. | 02-25-2010 |
20100055725 | SYSTEM FOR ASSAYS OF AMINOTRANSFERASE - An assay system ( | 03-04-2010 |
20100068741 | ASSAY SYSTEM FOR ADENOSINE TRIPHOSPHATE AND CREATINE KINASE - An assay method includes providing a luminescent nanocrystal; combining a solution having an adenosine triphosphate molecule; and displaying a light emission by the luminescent nanocrystal and the solution combined. | 03-18-2010 |
20100068742 | Methods - A method for identifying a compound expected to be useful in modulating, for example inhibiting, LRRK2 protein kinase activity, the method comprising the steps of (1) determining whether a test compound modulates, for example inhibits, the protein kinase activity of a LRRK2 polypeptide on a substrate polypeptide and (2) selecting a compound which modulates, for example inhibits, the said LRRK2 polypeptide protein kinase activity, wherein the substrate polypeptide comprises the sequence (W/F/R/K)(W/F/R/K)(R/K)(F/W/H/R)(Y/W/R)( | 03-18-2010 |
20100068743 | Method for predicting response of cancer patient to anticancer drug treatment - A method predicts a response of a cancer patient to anticancer drug based on a cell cycle profile score obtained by analyzing a malignant tumor of the cancer patient, wherein the method can predict a disease outcome including a complete response, a partial response, stable disease, no response, and time to progression of disease as patient's response to anticancer drug therapy. | 03-18-2010 |
20100075354 | MARKER FOR IDENTIFICATION OF TISSUE TYPE OF EPITHELIAL OVARIAN CANCER, AND METHOD FOR DETERMINATION OF THE OCCURRENCE OF EPITHELIAL OVARIAN CANCER BASED ON TISSUE TYPE BY USING THE MARKER - It is provided a method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type in view of molecular typing which is different from a conventional histopathology, and a marker for identification of a tissue-type of epithelial ovarian cancer. A method for identification of the morbidity of epithelial ovarian cancer based on a tissue-type, comprising: subjecting a sample originated from an individual of interest to a treatment for detecting at least one selected from the group consisting of biological molecules specifically showing an upregulation in expression in a specific tissue-type of epithelial ovarian cancer, and/or at least one selected from the group consisting of biological molecules specifically showing a downregulation in expression in a specific tissue-type of epithelial ovarian cancer, and identifying whether or not the significant detection of the protein is achieved, thereby identifying the tissue-type. | 03-25-2010 |
20100081153 | CANCER ASSOCIATED PROTEIN KINASES AND THEIR USES - Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. | 04-01-2010 |
20100086955 | Small Molecule Inhibitors of Ghrelin O-Acyltransferase - Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition. | 04-08-2010 |
20100086956 | DETECTION OF HIV-RELATED PROTEINS IN URINE - A method for detecting HIV infection in a mammal is disclosed. The method contains the steps of isolating exosomes from a urine sample of a mammal and detecting the presence of HIV-specific biomarker in said isolated exosomes. A method for diagnosing a mammal with an HIV-associated disease, in particular, HIV-associated nephropathy is also disclosed. | 04-08-2010 |
20100093008 | PHOSPHO-SPECIFIC ANTIBODIES TO FLT3 (TYR969) AND USES THEREOF - The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML). | 04-15-2010 |
20100099126 | METHOD OF CALCULATING ENZYMATIC REACTION RATE, COMPUTER PROGRAM PRODUCT AND METHOD OF DETERMINING AMOUNT OF ENZYME IN SAMPLE - A method of calculating an enzymatic reaction rate using the largest frequency value of a slope of a sub-group, a computer program product capable of performing the method of calculating an enzymatic reaction rate, and a method of determining the amount of an enzyme in a sample are provided. | 04-22-2010 |
20100105092 | LIPOLYTIC ENZYME VARIANTS - Variants with increased acyl transferase activity can be designed on the basis of a three-dimensional model by making amino acid alterations near the active Ser of lipolytic enzymes such as | 04-29-2010 |
20100112615 | GLYCOSYLTRANSFERASE ACTIVITY - We describe the production of nucleotide sugars other than uridine diphosphate glucose (UDP-glucose), for example UDP-rhamnose, and the use of these nucleotide sugars in the modification of acceptor molecules. | 05-06-2010 |
20100112616 | NOVEL BETA-GALACTOSIDE-a2,6-SIALYLTRANSFERASE, A GENE ENCODING THEREOF, AND A METHOD FOR ENHANCING ENZYME ACTIVITY - The present invention provides an extremely useful and novel β-galactoside-α2,6-sialyltransferase having an optimum reaction pH in a neutral to alkaline range, and a nucleic acid encoding the sialyltransferase. The present invention further provides a vector carrying a nucleic acid encoding the sialyltransferase, and a host cell transformed with the vector, as well as a method for producing a recombinant β-galactoside-α2,6-sialyltransferase. | 05-06-2010 |
20100112617 | Evaluating RTK Target Drugs - Methods of evaluating receptor tyrosine kinase drug efficacy are demonstrated. The methods generally relate to evaluation methods using phospho-RTK over total RTK ratio (pRTK/tRTK). An algorithm is provided that allows the user to combine the pRTK/tRTK ratios from several kinase together with other kinds of measurements to obtain a PDX value that is indicative of drug efficacy. | 05-06-2010 |
20100136592 | Photo-Induced Damage Mitigating Agents and Preparation and Methods of Use Thereof - Compositions, devices, systems and methods for reducing and/or preventing photo-induced damage of one or more reactants in an illuminated analytical reaction by addition of one or more photo-induced damage mitigating agents to the reaction mixture and allowing the reaction to proceed for a period that is less than a photo-induced damage threshold period. | 06-03-2010 |
20100136593 | METHOD FOR DIAGNOSING AND DISTINGUISHING STROKE AND DIAGNOSTIC DEVICES FOR USE THEREIN - A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject. | 06-03-2010 |
20100143956 | PREDICTIVE RENAL SAFETY BIOMARKERS AND BIOMARKER SIGNATURES TO MONITOR KIDNEY FUNCTION - Biomarker signatures were identified which can be used to diagnose or predict kidney or liver toxicity and more specifically renal tubular toxicity as a consequence of disease or drug treatment. | 06-10-2010 |
20100151505 | METHODS FOR MODULATING THERMOSTABILITY AND ACID TOLERANCE OF MICROBES - The present invention relates a method for modulating thermostability or acid tolerance of a microbe, comprising the steps of: (a) conferring a substitution mutation to a homoserine o-succinyltransferase (MetA)-encoding nucleotide sequence; and (b) transforming the MetA-encoding nucleotide sequence into a microbial cell. The mutated MetA of the present invention shows stability notably enhanced at high-temperatures and/or under acid conditions or decreased at mild temperature, and the microbe, particular bacteria expressing the mutated MetA of the present invention represents a growth rate improved in a vigorous environment such as higher-temperatures and/or lower acid conditions. | 06-17-2010 |
20100151506 | Chloroacetamidine Based Inhibitors and Activity Based Probes for the Protein Arginine Methytransferases - In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead. | 06-17-2010 |
20100173337 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS - Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. | 07-08-2010 |
20100173338 | Biomarkers for Cancer Sensitivity and Uses Thereof - Disclosed herein are biomarkers and uses thereof for evaluating anti-cancer efficacy and sensitivity. | 07-08-2010 |
20100173339 | PLATELET ACTIVATION MARKERS AS INDICATORS FOR ANTI-PLATELET THERAPY - Methods for determining the appropriateness of anti-platelet therapy in a patient with a platelet-affected disease. The Mean Platelet Component value in a patient blood sample is determined corresponding to the patient's platelet activation status. A high platelet activation status indicates the appropriateness of anti-platelet therapy. | 07-08-2010 |
20100184107 | PROTEIN TRAFFICKING - The present invention relates, in general, to protein trafficking, and, in particular, to a method of measuring protein trafficking to and from a plasma membrane. | 07-22-2010 |
20100203563 | Systems and Methods for Analyzing Persistent Homeostatic Perturbations - This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress. | 08-12-2010 |
20100209950 | GRANULOCYTE-BASED METHODS FOR DETECTING AND MONITORING IMMUNE SYSTEM DISORDERS - Methods are provided for determining a subject's susceptibility to an allergic reaction upon exposure to an offending allergen. Methods are also provided for determining and monitoring a subject's responsiveness to ongoing allergy treatment | 08-19-2010 |
20100216176 | NOVEL METHOD FOR SEQUENCE DETERMINATION USING NMR - The invention relates to methods for analyzing polysaccharides. In particular, compositional and sequence information about the polysaccharides are derived. Some methods use NMR in conjunction with another experimental method, such as, capillary electrophoretic techniques for the analysis. | 08-26-2010 |
20100221763 | Specific Acceptors for Transferases to Saccharides and Method for Obtaining and Using Same - A method for determining substrates specific for a transferase enzyme selected from the group consisting of glycosyltransferases and sulfotransferases. The method includes the steps of:
| 09-02-2010 |
20100227349 | USE OF LYMPHOCYTES TO MEASURE ANTHRAX LETHAL TOXIN ACTIVITY - It is disclosed herein that isolated lymphocytes, such as human B-cells and CD4 | 09-09-2010 |
20100227350 | Method of Screening Substance Useful in Treating Disease With the Use of GPR40 and Phospholipase - The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like. | 09-09-2010 |
20100227351 | METHOD OF DETECTING AND SEPARATING SERUM GAMMA-GLUTAMYL TRANSFERASE (GGT) ISOFORMS IN A SAMPLE OF BIOLOGICAL FLUID AND THE ENZYME ISOFORMS THEREBY OBTAINED - A method is described for detecting the gamma-glutamyl transferase enzyme isoforms (GGT, EC 2.3.2.2) in a sample of biological fluid, such as for example plasma or serum. The method comprises an HPLC separation step of the sample proteins based on the molecular size and a second step for detecting the GGT isoforms by post-column reaction with a GGT enzyme substrate capable of generating a detectable final product, preferably by spectrophotometric or fluorimetric means. The GGT isoforms can be separated by ultra-centrifugation, thereby obtaining three enzymatic isoforms characterised by molecular weights of approximately 2000, 940, and 140 KDa, respectively. | 09-09-2010 |
20100233743 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES - This invention relates to fluorescent probes for identification of compounds binding to protein kinases, for measurement of the affinity of inhibitors of protein kinases, and determination of the active concentration of protein kinases binding to the probe. Bisubstrate-analog character of the probe enables the simultaneous evaluation of inhibitors targeted to both ATP binding site and/or substrate protein/peptide binding domain of the kinase. High affinity of the probe (K | 09-16-2010 |
20100240080 | KINASE AND PHOSPHATASE ASSAYS - Compositions, methods, and kits for detecting and monitoring kinase, phosphatase and protein post-translational modification activity are described. The compositions typically include a peptide, a detectable moiety, and a protease cleavage site. Modification of a peptide by a kinase, phosphatase or other protein post-translational modification alters the proteolytic sensitivity of the peptide, resulting in a change of a detectable property of the composition. Panel assays for determining substrates or modulators of kinase, phosphatase or other protein post-translational modification activity are also described. | 09-23-2010 |
20100240081 | SEPRASE AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery. | 09-23-2010 |
20100248280 | Method for Identifying a Compound that Modulates Telomerase Activity - The present invention relates to a method for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain of telomerase and testing the compound for its ability to modulate the activity of telomerase. | 09-30-2010 |
20100267067 | Synthase Inhibitor Screening Method - The present invention relates to a method for selecting at least one host cell secreting one or more active enzyme of interest, said method comprising the steps of: a) providing a growth medium comprising one or more synthase inhibitor, which inhibits the synthesis of at least one essential compound in the host cell, and further comprising one or more component, which in the presence of the one or more active enzyme of interest is converted into the at least one essential compound, thereby allowing the host cell to grow; b) cultivating the host cell in or on the growth medium of step (a); and c) selecting at least one host cell capable of growing in or on the growth medium of step (a), which host cell secretes one or more active enzyme of interest. | 10-21-2010 |
20100273195 | SKIN AGING-PREVENTING OR IMPROVING AGENT - The present invention provides a skin aging-preventing or improving agent. The agent contains a substance capable of enhancing the expression level of Rho kinase or myosin light-chain kinase. According to the present invention, aging of the skin such as sagging of the skin, wrinkle formation, or loss of skin elasticity can be prevented or the skin can be improved. | 10-28-2010 |
20100279327 | METHOD OF TREATING DISEASES WITH PARP INHIBITORS - The present invention relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a sample of a subject, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in the subject with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. The present invention also relates to methods of identifying a disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP. The method further comprises of treating the disease in a subject population with the PARP modulators. The methods relate to identifying up-regulated PARP in a disease and making a decision regarding the treatment of the disease with PARP inhibitors. The extent of PARP up-regulation in a disease can also help in determining the efficacy of the treatment with PARP inhibitors. | 11-04-2010 |
20100285511 | TRANSFORMED CELL WITH ENHANCED SENSITIVITY TO ANTIFUNGAL COMPOUND AND USE THEREOF - The present invention provides a transformed cell in which a polynucleotide having a nucleotide sequence encoding an amino acid sequence of an osmosensing histidine kinase having no transmembrane region is introduced in a functional form into a cell deficient in at least one hybrid-sensor kinase, a method of assaying the antifungal activity of a test substance using the transformed cell, and a method of searching an antifungal compound using the method, and the like. | 11-11-2010 |
20100291605 | ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES - Disclosed are novel methyltransferase assay methods, comprising: including, in a reaction mixture for a methyltransferase activity, a purified or recombinant adenosine nucleosidase activity that catalyses release of an adenine or adenine derivative moiety from a transmethylation product, and a purified or recombinant adenine deaminase activity that catalyses deamination of the released moiety to hypoxanthine or respective derivative and ammonia, wherein the methyltransferase activity is rate-limiting; and determining the methyltransferase activity by spectrophotometric or chromatographic monitoring of the coupled deamination reaction products, or of subsequent enzymatic or chemical reactions coupled thereto. Coupled oxidation of the hypoxanthine to uric acid and hydrogen peroxide is optionally affected using purified or recombinant xanthine oxidase, wherein the methyltransferase activity is rate-limiting, and wherein determining the methyltransferase activity comprises monitoring of the coupled oxidation reaction. Variations are disclosed comprises monitoring of reaction products (e.g., to detect NH3, Hypoxanthine, H2O2, and Uric Acid). | 11-18-2010 |
20100291606 | SCREENING SYSTEM FOR DETECTING INHIBITORS OF HIV INTEGRASE-LEDGF/p-75 INTERACTION - The development and validation of a cell-based, homogeneous high throughput screening (HTS) assay for small compounds inhibiting the HIV integrase-LEDGF/p75 interaction is described herein. The HTS strategy has the potential to identify small-molecules interfering with the interaction of HIV integrase-LEDGF/p75. These small molecules represent starting scaffolds for therapeutic drug development. | 11-18-2010 |
20100291607 | TRANSFORMED CELL WITH ENHANCED SENSITIVITY TO ANTIFUNGAL COMPOUND AND USE THEREOF - The present invention provides a transformed cell in which a polynucleotide having a nucleotide sequence encoding an amino acid sequence of an osmosensing histidine kinase having no transmembrane region is introduced in a functional form into a cell deficient in at least one hybrid-sensor kinase, a method of assaying the antifungal activity of a test substance using the transformed cell, and a method of searching an antifungal compound using the method, and the like. | 11-18-2010 |
20100297681 | FLUORESCENT PROBE FOR MEASUREMENT OF GLUCURONATE TRANSFERASE - A fluorescent probe for measurement of UDP-glucuronosyltransferase, which comprises a fluorescein derivative, wherein in the fluorescein derivative, the 2-carboxy group on the benzene ring of fluorescein is replaced with another monovalent substituent, provided that said substituent is a substituent other than sulfo group, and the substituent does not have carboxy group or sulfo group, and wherein the fluorescein derivative may have an arbitrary substituent at a position on the benzene ring other than the 2-position, and the fluorescein derivative may have a substituent selected from the group consisting of an alkoxy group and a halogen atom at the 2-position and/or the 7-position of fluorescein. | 11-25-2010 |
20100311093 | METHOD OF AMPLIFYING ATP AND USER THEREOF - The ATP amplification method is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. Also provided is an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method. | 12-09-2010 |
20100323379 | SLEEP APNEA - This document relates to methods and materials involved in diagnosing sleep apnea and assessing the effectiveness of a treatment for sleep apnea. For example, methods and materials for using markers to determine whether or not a mammal (e.g., a human) has sleep apnea are provided. In addition, methods and materials that can be used to determine whether or not a mammal (e.g., a human) responds to a sleep apnea treatment are provided. | 12-23-2010 |
20100323380 | METHODS FOR DIAGNOSING BLOOD VESSEL REOCCLUSION - The present invention features a method of diagnosing blood vessel reocclusion in a subject by detecting increased levels of sFLT-1 in a biological sample from the subject. | 12-23-2010 |
20110020853 | COMPOSITIONS AND METHODS FOR DETECTING PHOSPHOMONOESTER - The invention provides a method of modifying a phosphomonoester moiety of a target compound. The method can include the steps of (a) providing a target compound having an electrophilic moiety and a phosphomonoester moiety; (b) contacting the target compound with a first carbodiimide compound under conditions for preferential addition of the first carbodiimide compound to the electrophilic moiety over the phosphomonoester moiety, thereby forming an electrophile-protected target compound; and (c) contacting the electrophile-protected target compound with a second carbodiimide compound and a nucleophilic compound under conditions for addition of the nucleophilic compound to the phosphomonoester. | 01-27-2011 |
20110045514 | METHODS FOR DETECTING MAJOR ADVERSE CARDIOVASCULAR AND CEREBROVASCULAR EVENTS - The present teachings relate to a method of assessing the probability of a major adverse cardiovascular or cerebrovascular event in a human. The method can include measuring a concentration, in a blood-based sample of a human, of a set of analytes, for example, alpha-fetoprotein, cancer antigen 125, glutathione S-transferase, and tissue factor. The method also can include determining a MACCE index for the set of analytes and identifying the human as having an increased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is greater than zero, or a decreased likelihood of a major adverse cardiovascular or cerebrovascular event if the MACCE index is less than or equal to zero. | 02-24-2011 |
20110045515 | METHOD TO DETECT HEMOLYTIC STREPTOCOCCUS AND OPTOELECTRICALLY DETERMINE RESULTS - A reagent is provided for the detection of an exotoxin protein produced by a betahemolytic | 02-24-2011 |
20110065136 | Methods and Devices for Detecting Glomerulonephritis and Associated Disorders - Methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining glomerulonephritis or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 03-17-2011 |
20110065137 | Methods and Devices for Detecting Obstructive Uropathy and Associated Disorders - Methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining obstructive uropathy or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | 03-17-2011 |
20110081671 | VASCULAR MARKERS IN THE REMODELING OF CARDIAC INJURY - The present invention is concerned with diagnostic means and methods. More specifically, the present invention relates to a method for diagnosing the angiogenic status of a subject suffering from myocardial infarction comprising determining the amounts of P1GF, sFLT1 and endoglin in a first sample of a subject obtained after myocardial infarction and in a second sample of the subject obtained after the first sample and comparing the amounts in the first sample with those in the second sample whereby the angiogenic status is diagnosed. The present invention also encompasses a method of determining whether a subject suffering from myocardial infarction is susceptible to a pro-angiogenic therapy. Finally, the present invention relates to a kit or a device for carrying out the method of the invention. | 04-07-2011 |
20110124021 | PHOSPHORYLATED FATTY ACID SYNTHASE AND CANCER - The disclosed invention relates to the detection of phosphorylated fatty acid synthase as a diagnostic and a component in the identification and treatment of cancer. The disclosed methods permit early and accurate diagnosis of cancer to enable more effective therapy and to enhance patient survival and quality of life. | 05-26-2011 |
20110124022 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES - Non-invasive methods are provided herein for the diagnosis of pre-diabetes and diabetes using biomarkers identified in a biological fluid, such as saliva. These biomarkers can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. | 05-26-2011 |
20110165601 | ASSAY SYSTEM - The present invention relates to materials and methods for performing assays directed to monitoring activity and function of intracellular components, such as proteins associated with organelles and other intracellular structures. In particular, the invention relates to permeabilised cell preparations and their use in studying activity of intracellular components, in particular for studying sarcoplasmic reticulum function. | 07-07-2011 |
20110165602 | EMISSION RATIOMETRIC INDICATORS OF PHOSPHOINOSITIDES - Emission ratiometric indicators of phosphoinositides comprise a fusion protein comprising a pleckstrin homology (PH) domain of Akt (also known as protein kinase B) and a “pseudoligand” containing acidic amino acid residues, which is sandwiched between resonance energy transfer (RET) pairs, such as cyan and yellow mutants of GFP (a FRET pair). Such indicators can be used, inter alia, to monitor spatiotemporal dynamics of phosphoinositides and in high throughput assays for inhibitors of PI3K, including drug screening assays. | 07-07-2011 |
20110165603 | SMALL MOLECULE FLUORESCENT SENSORS FOR DETECTION OF POST-TRANSLATIONALMODIFICATIONS AND PROTEIN INTERACTIONS IN BIOASSAYS - The present invention relates to novel compounds which are capable as acting as fluorescent sensors or which are precursors for these and for the use of these for the assay of biological processes such as posttranslational modifications of biological molecules such as phosphorylation, de-phosphorylation, proteolytic cleavage, phosphodiesterase mediated hydrolysis of cyclic nucleotides, methylation, acetylation of proteins peptides, DNA, lipids and the detection of biomolecule interactions (e.g., protein-protein interactions). A small molecule sensor is described which can associate to phosphorylated biological targets via metal ion—phosphate association. The association event can be monitored as fluorescence quench, sensitized emission, fluorescence polarization or a combination thereof. The sensor is useful for determining enzyme | 07-07-2011 |
20110195439 | SYSTEMS AND METHODS FOR DETERMINING CARDIAC CONDITIONS - Systems and methods for determining cardiac conditions. According to at least one embodiment of a stabilizing system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for cardiovascular disease in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker. | 08-11-2011 |
20110201037 | USE OF ERYTHROPOIETIN TO DEVELOP SMALL MOLECULE INHIBITORS OF JANUS KINASE-2 - The invention pertains to a method for identifying compounds that inhibit the erythropoietin-induced JAK2 kinase activity in vivo. The present invention provides a method for detecting small molecule JAK2 inhibitors in a rapidly created rodent model that phenocopies human PV through Epo stimulation. The method comprises the steps of (a) dosing a rodent with erythropoietin (Epo) and a test compound, (b) collecting blood samples after the dose is administered, (c) measuring phosphorylated STAT5 levels in the blood sample, and (d) determining JAK2 inhibitor levels in the blood samples. | 08-18-2011 |
20110201038 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries. | 08-18-2011 |
20110207157 | Labelling of Fusion Proteins With Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O | 08-25-2011 |
20110212474 | ABNORMAL ALTERATIONS OF PKC ISOZYMES PROCESSING IN ALZHEIMER'S DISEASE PERIPHERAL CELLS - The present invention provides a method for the diagnosis of AD from non-AD conditions by using a PKC Isozyme Index obtained by determining ratios of ratios of different PKC Isozymes in peripheral cells of a test subject in the absence and presence of a beta-amyloid peptide, and optionally, in the presence of a PKC activator. | 09-01-2011 |
20110212475 | Fluorescently Or Spin-Labeled Kinases For Rapid Screening And Identification Of Novel Kinase Inhibitor Scaffolds - The present invention relates to a kinase labeled at an amino acid having a free thiol or amino group, wherein said amino acid is naturally present or introduced in the activation loop of said kinase, with (a) a thiol- or amino-reactive fluorophore sensitive to polarity changes in its environment; or (b) a thiol-reactive spin label, an isotope or an isotope-enriched thiol- or amino-reactive label, such that said fluorophore, spin label, isotope or isotope-enriched label does not inhibit the catalytic activity and does not interfere with the stability of the kinase. The invention furthermore relates to a method of screening for kinase inhibitor, a method of determining the kinetics of ligand binding and/or of dissociation of a kinase inhibitor and a method of generating mutated kinases suitable for the screening of kinase inhibitors using the kinase of the present invention. | 09-01-2011 |
20110229917 | MULTIPLEX LIQUID TISSUE.TM. METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES AND CELLS - The invention provides methods for multiplex analysis of biological samples of formalin-fixed tissue samples. The invention provides for a method to achieve a multiplexed, multi-staged plurality of Liquid Tissue preparations simultaneously from a single histopathologically processed biological sample, where the protocol for each Liquid Tissue preparation imparts a distinctive set of biochemical effects on biomolecules procured from histopathologically processed biological samples and which when each of the preparations is analyzed can render additive and complementary data about the same histopathologically processed biological sample. | 09-22-2011 |
20110244496 | HIV REVERSE TRANSCRIPTASE COMPOSITIONS AND METHODS - The present invention provides engineered novel variants of human immunodeficiency virus reverse transcriptase (HIV-RT) capable of being expressed in large quantity and that with polymerase and RNase H activity in a form that facilitates crystallization and high resolution structure resolution following X-ray diffraction. The present invention facilitates high resolution determination of RT in complexes with RT drugs and RT inhibitors, and provides methods for systematic generation of variants and for structure based identification and design of novel RT inhibitors. | 10-06-2011 |
20110244497 | METHOD FOR JUDGING SUSCEPTIBILITY OF CANCER CELLS TO ANTHRACYCLINE ANTICANCER AGENT AND COMPUTER PROGRAM - The present invention provides a method for judging susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent comprising steps of: measuring expression levels of GST-π of cancer cells contained in a biological sample; and judging the susceptibility of cancer cells contained in a biological sample to an anthracycline anticancer agent as high when the expression level of GST-π obtained by the measuring process is high, and a computer program which makes a computer execute the method. | 10-06-2011 |
20110244498 | TYROSINE KINASE-INDUCIBLE DOMAINS - The present invention relates to a tyrosine kinase-inducible domain (pKID) and uses thereof. An isolated polypeptide comprising the pKID, and an isolated polynucleotide comprising a nucleic acid sequence encoding the pKID are provided. Also provided are methods for determining tyrosine kinase and/or phosphatase activity in a sample and for identifying an agent that inhibits a tyrosine kinase or phosphatase using a polypeptide comprising the pKID. | 10-06-2011 |
20110262943 | REAGENT KIT FOR MEASURING FRESHNESS - A reagent kit for measuring freshness, which can be stored at a relatively high temperature with high storage stability, is obtained by lyophilizing reagent solutions each containing a plurality of enzymes and an enzyme protecting agent. The reagent kit includes a first reagent and a second reagent. The first reagent is obtained by drying a frozen product of a first reagent solution containing XOD, NP, an enzyme protecting agent, and a color former under reduced pressure at a temperature not higher than the glass transition temperature (Tg). The second reagent is obtained by drying a frozen product of a second reagent solution containing XOD, NP, AP, an enzyme protecting agent, and a color former under reduced pressure at a temperature not higher than the glass transition temperature (Tg). The enzyme protecting agent is sucrose and/or gelatin, and the color former develops a color by conjugation with a reaction of decomposing Hx into xanthine and uric acid by XOD. | 10-27-2011 |
20110262944 | CONSTRUCTION AND CRYSTALLIZATION OF EXPRESSION SYSTEM FOR RNA POLYMERASE PB1-PB2 PROTEIN DERIVED FROM INFLUENZA VIRUS - The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs. | 10-27-2011 |
20110269161 | Methods, Compositions and Kits for High Throughput Kinase Activity Screening Using Mass Spectrometry and Stable Isotopes - A mass-spectrometry-based method and substrates are provided herein for large scale kinome activity profiling directly from crude lysates using 90 chemically synthesized peptide substrates with amino acid sequences derived from known phosphoproteins. Quantification of peptide phosphorylation rates was achieved via the use of stable isotope labeled synthetic peptides. Half of these peptides immediately or rapidly showed robust and site-specific phosphorylation after incubation with serum-starved HEK293 cell lysate. A method and substrates for obtaining 90 simultaneous activity measurements in a single-reaction format were developed and validated. Activating kinase pathways through insulin or EGF stimulation reproducibly altered the phosphorylation rates of peptides derived from known pathway protein substrates. While examining cell-cycle-specific activities with the panel, a peptide derived from phosphoinositide 3-kinase regulatory subunit demonstrated mitotic and tyrosine-specific phosphorylation, which was confirmed to be a Src kinase site in vivo. The kinome activity profiling strategy was successfully applied with lysates of each of: cells manipulated by various combination of mitogen stimulation, pharmacological perturbation and siRNA-directed kinase knockdown; seven different breast cancer cell lines treated with gefitinib; and each of normal and cancerous tissue samples from renal cell carcinoma patients. This method concurrently measures multiple peptide phosphorylation rates to provide a diagnostic fingerprint pattern for activated kinases, protein phosphatases, modulators of these enzymes, and pathways (kinome) from as little starting material as a few cells. | 11-03-2011 |
20110275102 | ACTIVATION OF MUTATED RAC-PK - The invention concerns RAC-PK and fragments thereof, as well as activators and inhibitors of RAC-PK for use as medicaments, particularly in the treatment of diseases concerned with abnormalities in processes modulated by insulin, such as cellular proliferation, insulin deficiency and/or excess blood sugar levels. Moreover, the invention provides RAC-PK for use in screening potential mimics or modulators thereof. A method for screening for agents capable of affecting the activity of GSK3 is also disclosed. The invention further provides a screening kit comprising the RAC-PK as an active principle, and a method for screening compounds which are candidate mimics or modulators of RAC-PK activity comprising detecting specific interactions between the candidate compounds and RAC-PK. There is also provided a process for activating RAC-PK comprising treatment thereof with a phosphatase inhibitor. | 11-10-2011 |
20110275103 | EMISSION RATIOMETRIC REPORTERS OF MEMBRANE PDK1 ACTIVATION - Phosphoinositide-dependent kinase 1 (PDK1) activity reporters can be used in high throughput assays for drug screening. | 11-10-2011 |
20110281288 | Reusable Nanowire Field Effect Transistor System for Detecting Biomolecular Interactions - A reusable nanowire field effect transistor for detecting biomolecular interactions. The field effect transistor contains nanowire covalently linked to a docking molecule, which is capable of binding to an anchor molecule in a reversible manner, i.e., at an association constant of 10 | 11-17-2011 |
20110281289 | QUANTIFICATION OF ENZYME ACTIVITY BY MASS SPECTROMETRY USING IMMOBILIZED SUBSTRATES - The disclosure relates to methods of analyzing the enzymatic activity of enzymes in samples containing a plurality of enzymes, using mass spectrometry. Immobilized substrates are employed. Purified enzymes and enzymes from crude cell lysates can be analyzed using the disclosed methods. | 11-17-2011 |
20110281290 | SOX-BASED KINASE SENSOR - Peptidyl sensors comprise a metal-binding peptide and one or two kinase recognition sequences with a hydroxyamino acid that can be phosphorylated in the presence of a kinase. | 11-17-2011 |
20110287462 | PROTEIN FRAGMENT COMPLEMENTATION ASSAY FOR THERMOPHILES - A protein fragment complementation assay for thermophiles is provided wherein a thermophilic bacteria having a temperature-sensitive adenylate kinase is transformed with one or more vectors having sequences encoding a first test peptide operatively fused to a first portion of a thermostable adenylate and a second test peptide operatively fused to a second portion of the thermostable adenylate kinase. Association of the first and second test peptides allows association of the first and second portions of the thermostable adenylate kinase and growth of the thermophilic bacteria at a temperature greater than 70° C. | 11-24-2011 |
20110306073 | METHOD AND COMPOSITIONS FOR DETERMINING ENZYMATIC ACTIVITY AND SPECIFICITY OF METHYLTRANSFERASES - The invention provides crystalline O-methyltransferases and isolated non-native O-methyltransferases as well as sets of their structural coordinates. Also provided are methods of predicting the activity or substrate specificity of putative O-methyltransferases, methods of identifying potential substrates of O-methyltransferases, and methods of identifying potential inhibitors of methyltransferases. | 12-15-2011 |
20110306074 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS - The present invention generally relates to materials and methods for exploiting glycosyltransferase reversibility for nucleotide diphosphate (NDP) sugar synthesis. The present invention provides engineered glycosyltransferase enzymes characterized by improved reaction reversibility and expanded sugar donor specificity as compared to corresponding non-mutated glycosyltransferase enzymes. Such reagents provide advantageous routes to NDP sugars for subsequent use in a variety of biomedical applications, including enzymatic and chemoenzymatic glycorandomization. | 12-15-2011 |
20110312005 | Enzymatic modification of cell-surface H antigen by glycosyltransferases - This invention relates to cells with modified blood group antigen expression. In particular, the invention relates to cells for use in haematology, immunohaemotology and immunology assays as serology controls. | 12-22-2011 |
20110318768 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT - The present invention provides a method for determining sensitivity of the tumor cells to an EGFR and/or HER | 12-29-2011 |
20110318769 | METHOD AND COMPOSITION FOR TARGETING VICIOUS CYCLES OF STRESSES AND INFLAMMATORY RESPONSES - The present invention provides methods and compositions for targeting the pathologically relevant bipolar actions of these master integrators without affecting the basal physiologically relevant functions. NFA can be used as marker of vicious cycles. Partial inhibition of NFA will be less toxic (in most cases) and more efficient for simultaneous partial inhibitions of all key mediators to terminate this vicious cycles for prevention and treatment of the long-term stresses and chronic inflammation-related diseases without causing any side effects and complications. Aberrant expression of NFA, master stress, and inflammation integrators play a role in orchestrating of vicious cycles. Aspects of the invention provide core technology for simultaneously targeting 12 hallmarks of cancer. | 12-29-2011 |
20120003676 | MASS SPECTROMETRY ASSAY FOR THIOPURINE-S-METHYL TRANSFERASE ACTIVITY AND PRODUCTS GENERATED THEREBY - Methods are described for measuring the amount of a methylation TPMT enzyme product in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying 6-MMP or isotopically labeled 6-MMP in a test sample utilizing mass spectrometric techniques and for using such methods to determine the activity of TPMT enzyme that is present in a sample. | 01-05-2012 |
20120028284 | TRAPPING COMPOUNDS AND METHOD FOR IDENTIFYING REACTIVE METABOLITES - A compound of formula (I) is useful to identify reactive metabolites. | 02-02-2012 |
20120040387 | METHOD AND REAGENT FOR MEASURING MEVALONIC ACID, 3-HYDROXYMETHYLGLUTARYL COENZYME A, AND COENZYME A - The present invention provides a method for measuring the concentration of an analyte in a test solution wherein the analyte is mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A, comprising the following steps (p) and (q): (p) a step of allowing an enzyme that catalyzes a reaction represented by Reaction Formula 1 and an enzyme that catalyzes a reaction represented by Reaction Formula 2 to act on a test solution containing mevalonic acid and/or 3-hydroxymethylglutaryl coenzyme A in the presence of a hydrogen acceptor X, a hydrogen donor Y, and coenzyme A; and (q) a step of measuring an amount of: a reduced hydrogen acceptor X that is produced; or an oxidized hydrogen donor Y that is produced; or a hydrogen acceptor X that is decreased; or a hydrogen donor Y that is decreased, wherein the hydrogen donor Y and the reduced hydrogen acceptor X are not the same. | 02-16-2012 |
20120058501 | OXIDIZED GLUTATHIONE ASSAY - The present invention provides an assay for detection of oxidized glutathione (GSSG). | 03-08-2012 |
20120064554 | METHODS FOR ASSAYING ENZYME ACTIVITIES - The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected. | 03-15-2012 |
20120064555 | QUANTITATIVE ANALYSIS OF A BIOLOGICAL SAMPLE OF UNKNOWN QUANTITY - Disclosed is a method for testing a modified specimen such as a dried blood spot, plasma or serum specimen, for an analyte of interest, such as cholesterol. In accordance with the disclosed subject matter, the level of the analyte of interest in the medium from which the modified specimen was obtained (e.g., from a patient's blood) is determined based on the level of an analyte in a solution formed from the modified specimen and on the level of at least one normalizing analyte. The analyte and normalizing analyte each may be an ion, compound, biochemical entity, or property of the specimen. Also disclosed are a fluid collector and a fluid collection device. | 03-15-2012 |
20120077214 | Systems And Methods For Predicting Response To Minoxidil For The Treatment Of Androgenetic Alopecia - Methods, processes, systems, and apparatuses are disclosed for predicting minoxidil response in the treatment of androgenetic alopecia based on colorimetric assay. | 03-29-2012 |
20120107852 | METHOD FOR PREPARING MODIFIED POLYPEPTIDES - Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve
| 05-03-2012 |
20120115176 | METHOD FOR DETECTING COMPOUNDS MODULATING DIMERS OF VFT DOMAIN MEMBRANE PROTEINS - The invention relates to a method for selecting compounds having a modulating effect on the activation state of a dimer of VFT-domain proteins expressed in cell membranes present in a measuring medium, said dimer consisting of a first protein and of a second protein, said proteins being identical or different, wherein this method comprises the following steps:
| 05-10-2012 |
20120122131 | SIMULTANEOUS DETECTION OF METABOLIC ENZYME ACTIVITY AND METABOLITE LEVELS - Provided are methods for detecting a metabolic disorder in an individual using mass spectrometry. One method involves (a) contacting a sample containing (i) a metabolically indicative enzyme and (ii) a metabolic analyte, with a substrate for the enzyme to produce a reaction admixture, under conditions wherein the enzyme is capable of acting on a corresponding substrate to generate a product, and wherein a protease inhibitor is present; (b) contacting the reaction admixture with a reagent that inhibits the ability of the enzyme to act on a corresponding substrate, wherein the metabolic analyte and the product are soluble in the reagent; to produce a test sample and (c) determining the presence or amount of the metabolic analyte and the product contained in the test sample using mass spectrometry, wherein a determined presence or amount of the metabolic analyte and the product correlates with presence or absence of the metabolic disorder. | 05-17-2012 |
20120164670 | METHODS AND KITS FOR MEASURING ENZYME ACTIVITY - The invention relates to methods and kits for measuring enzyme activity, including enzymes that produce nicotinamide. | 06-28-2012 |
20120178116 | POLYPEPTIDES FOR IDENTIFYING FUNGICIDALLY ACTIVE COMPOUNDS - The invention relates to a combination of polypeptides from phytopathogenic fungi having the biological activity of an aurora kinase and the function of an aurora kinase activator, to nucleic acids coding therefore, to the use of the polypeptides and nucleic acids for identifying modulators of an aurora kinase, to processes for identifying such modulators and to the use of these modulators as fungicides. | 07-12-2012 |
20120190053 | Method of determining factor XIII with the aid of plasma-based reference material - The present invention is in the field of in-vitro diagnostics and relates to a method of determining the blood-clotting factor XIII (factor XIII, F XIII) with the aid of plasma-based reference material, and a test kit for carrying out the method. | 07-26-2012 |
20120202233 | Methods and uses of KSR kinase, and mutations thereof - Mutant KSR proteins are disclosed. The mutants include single amino acid substitutions, leading to either a loss of kinase activity or a loss of scaffolding activity. Also disclosed are methods of screening compounds for inhibitors of KSR kinase activity or KSR scaffolding activity. In some embodiments, the screening methods include protein complementation assays in which nucleic acids encoding fusion constructs comprising enzyme portions and kinase dimerization domains are expressed in cells. Inhibitors of dimerization can be indicated by loss of enzyme activity. | 08-09-2012 |
20120202234 | METHODS AND COMPOSITION FOR ISOPRENOID DIPHOSPHATE SYNTHESIS - Provided herein are methods and compositions relating to the synthesis of isoprenoid diphosphates using a mutated isopentenyl phosphate kinase. | 08-09-2012 |
20120208220 | METHOD AND KIT FOR DETECTING FOLTATE - A method and a kit for detecting folate are disclosed. The method includes the following steps: (a) mixing a sample and an extraction buffer to form a mixture, heating and then cooling the mixture, and separating a supernatant from the mixture by centrifugation; (b) adding a recombinant γ-glutamyl hydrolase (GGH) and a folate conversion enzyme to the supernatant to drive catalysis; (c) stopping the catalysis; and (d) analyzing the supernatant by high performance liquid chromatography. | 08-16-2012 |
20120219978 | Method and System for Detection of Chloramphenicol - Fast and simple method of detecting the presence of chloramphenicol, a harmful compound if present in food products. The method makes use of a mutant chloramphenicol acetyltransferase (CAT) and a fluorophore-linked chloramphenicol in a system where chloramphenicol and the fluorophore-linked chloramphenicol competes for the active site of the mutant CAT. Because the fluorophore-linked chloramphenicol reduces its fluorescence upon binding to the active site and vice versa increases its fluorescence upon being displaced from the active site by the presence of unmodified chloramphenicol in a sample, the increase of fluorescence caused by a testing sample indicates the presence of chloramphenicol. | 08-30-2012 |
20120237961 | Labelling of Fusion Proteins with Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O | 09-20-2012 |
20120244566 | Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof - Methods and materials use template-directed assembly of polypeptides and optionally additional reagents to analyze the functionality of membrane-associated proteins, such as, for example, portions of transmembrane proteins, membrane-associated proteins (including receptor tyrosine kinases, and non-receptor tyrosine and serine-threonine kinases), and other proteins that bind to transmembrane proteins and membrane-associated proteins, and to analyze the effect of test compounds or mutations on the functionality of same. The methods and materials of the present application provide a more native-like environment for analyzing the functionality of membrane-associated proteins, and thus provide effective tools for studies involving the detection of the level of enzyme activity of such proteins in an environment that closely resembles the native environment in the cell, and for novel manufacturing processes. | 09-27-2012 |
20120244567 | HUMAN EMBRYONIC STEM CELLS FOR HIGH THROUGHOUT DRUG SCREENING - Methods of culturing embryonic stem cells in a format suitable for high-throughput screening (HTS) are provided. In addition compounds that show differential cytotoxic/protective activity on embryonic stem cells (ESCs) and neurological stem cells (NSCs) are provided. | 09-27-2012 |
20120252047 | SALICYLIC ACID DERIVATIVES WITH FLUOROPHORES AND METHOD OF MAKING AND USING THE SAME - A latent fluorophore is derived from salicylic acid, and containing a fluorogenic group and a moiety represented by formula I | 10-04-2012 |
20120258481 | CROSS-LINKING ATP ANALOGS - An adenosine 5′-triphosphate analogs modified at the gamma-phosphate with a reactive reagent. A method of forming the analog by activating a 4-amino benzoic acid, incubating the activated acid to obtain an amine, and coupling the amine with ATP in the presence of water soluble EDCI. A method of detecting the efficacy of a therapeutic by adding a gamma-phosphate modified ATP analog to a protein substrate, reacting the target proteins with the ATP analog, and analyzing the resulting cross-linked product, wherein the amount of product present correlates to the efficacy of the therapeutic is also provided. | 10-11-2012 |
20120258482 | PCNA METHYLTRANSFERASE - Proliferating cell nuclear antigen (PCNA)-dependent glutamate methyltransferases are disclosed that can methylesterify one or more glutamic acid or aspartic acid residues of PCNA. | 10-11-2012 |
20120264151 | SYSTEM AND METHOD FOR DIAGNOSING LYMPHOMA IN CATS - The invention provides a method and a system for diagnosing lymphoma in cats. The system allows a care giver to measure the enzymatic activity of thymidine kinase in a blood sample. The invention teaches that when the enzymatic activity of thymidine kinase in the blood stream of a cat is above 15.5 Units per liter, the cat has a high probability of having lymphoma. The invention allows for initial diagnosis, follow up after treatment for lymphoma and/or monitoring for example in breeds that prone to have lymphoma. | 10-18-2012 |
20120264152 | DIAGNOSTIC AND PROGNOSTIC ASSAYS BASED ON CIRCULATING TYROSINE KINASE ACTIVITY - Provided herein are methods for the diagnosis, prognosis, or management of diseases, such as cancer, by measuring the tyrosine kinase activity in acellular body fluids. Further provided are methods of predicting response to therapy in certain populations of cancer patients by contacting an acellular body fluid sample from a patient with a test agent, such as a tyrosine kinase inhibitor, and then measuring the effect of the test agent on tyrosine kinase activity in the sample. | 10-18-2012 |
20120270250 | TEST SYSTEM FOR MEASURING MEST ACTIVITY AS WELL AS METHODS AND USES INVOLVING THE SAME - The present invention relates to a test system for measuring MEST activity, a method for screening for a ligand for MEST and the use of the test system for the identification of a MEST ligand, particularly a MEST inhibitor. | 10-25-2012 |
20120276567 | TALAROMYCES TRANSFORMANTS - The invention relates to a | 11-01-2012 |
20120301909 | SULFOTRANSFERASE ASSAY - Assays and methods for detecting and/or quantifying activity of a test sulfotransferase comprising by releasing a free phosphate from the PAP produced by the sulfotransferase reaction and detecting the free phosphate. The assay can includes gPAPP, a free phosphate detector and an optional control sulfotransferase. The method includes combining a test sulfotransferase with the substrate of the sulfotransferase, PAPS and gPAPP and detecting the free phosphate. The level of free phosphate directly correlates to the activity of the sulfotransferase. The assay and methods can be used to screen agents for their effect upon sulfotransferase activity. | 11-29-2012 |
20120315658 | AMELIORATION OF METABOLIC SYNDROME USING PHYSIOLOGICAL FUNCTIONS OF SPHINGOMYELIN SYNTHASE SMS2, OR SCREENING METHODS FOR AMELIORATING AGENTS - Disclosed is a method for screening for a medicinal agent that can decrease a body weight, a medicinal agent that can reduce a visceral fat, a medicinal agent that can reduce a triglyceride in the liver, and a medicinal agent that can ameliorate obesity and fatty liver. The method involves a step of measuring the inhibitory activity of a candidate substance on a sphingomyelin synthase, wherein the candidate substance is determined to have at least one function selected from the group consisting of an anti-obesity agent, a visceral fat-reducing agent, a fatty liver-treating agent and an adiponectin expression enhancer when the candidate substance has an inhibitory activity on the sphingomyelin synthase. | 12-13-2012 |
20130004979 | GLYCOSYLTRANSFERASE REVERSIBILITY FOR SUGAR NUCLEOTIDE SYNTHESIS AND MICROSCALE SCANNING - The present invention generally relates to materials and methods for exploiting glycosyltransferase reversibility for nucleotide diphosphate (NDP) sugar synthesis. The present invention provides engineered glycosyltransferase enzymes characterized by improved reaction reversibility and expanded sugar donor specificity as compared to corresponding non-mutated glycosyltransferase enzymes. Such reagents provide advantageous routes to NDP sugars for subsequent use in a variety of biomedical applications, including enzymatic and chemo-enzymatic glycorandomization. | 01-03-2013 |
20130011870 | Method For Assaying Diseases Characterized By Dyslipidemia - A method for diagnosing a disease or for evaluating the risk to develop a disease which is characterized by dyslipidemia in humans, in particular for diagnosing atherosclerosis, coronary heart disease, peripheral vascular disease, stroke, metabolic syndrome, diabetes (type I and II) and diabetes related sequale (diabetic polyneuropathy, diabetic retinopathie or diabetic nephropathie) as well as lipid associated neuropathies (like Charcot-Marie-Tooth neuropathies such as hereditary sensory and autonomous neuropathy type 1 (HSAN1)) by measurement of atypical products of serine palmitoyltransferase. | 01-10-2013 |
20130040327 | Methods for Identifying Allosteric and Other Novel Acyl-Coenzyme A:Cholesterol Acyltransferase Inhibitors - The present invention is a method for identifying compounds that are allosteric and/or other novel ACAT inhibitors that is based on the novel finding that pregnenolone is a substrate for ACAT; esterification of pregnenolone by ACAT is dramatically activated when cholesterol is present in the assay. The method comprises measuring the esterification of pregnenolone by ACAT under two different conditions: with cholesterol, or without cholesterol. This method can be used to test and categorize various candidate ACAT inhibitors as allosteric or other novel ACAT inhibitors, or it can be used in high-throughput screening for identifying such ACAT inhibitors. | 02-14-2013 |
20130045498 | VISCOSITY PRESSURE ASSAY - The present invention relates to methods of determining enzyme activity in a fluid, wherein the activity over time provides a viscosity-change in the fluid, by the use of a device (FIG. | 02-21-2013 |
20130059319 | METHOD AND A DEVICE FOR DETECTING, CLASSIFYING, AND IDENTIFYING PARTICLES, AEROSOLS, AND/OR VAPORS IN THE AIR - A method and device are disclosed for continuously detecting, classifying and identifying toxic particles, aerosols and/or vapor in an air sample, in near real time by directing an air sample containing an optional target analyte, in the form of particles, aerosols and/or vapors, enzyme(s), and enzyme substrate(s), to a surface of a collection matrix for forming a biocatalytic reaction product of a plurality of freely mobile optical reporters, and by using a light source with optical reader to interpret the signal from the optical reporter, enabling the detection, classification and identification of toxic particles, aerosols and/or vapor in the air sample. | 03-07-2013 |
20130065262 | PHOSPHATASE COUPLED GLYCOSYLTRANSFERASE ASSAY - A kit for detecting or measuring glycosyltransferase activity including a first reagent comprising a phosphatase and a second reagent comprising a free phosphate detector, and method of detecting and measuring glycosyltransferase activity. A sugar donor, an acceptor substrate, a glycosyltransferase enzyme and a phosphatase are combined and the amount of free phosphate present in the product is measured and used to calculate the activity of the glycosyltransferase enzyme. | 03-14-2013 |
20130078660 | METHODS AND COMPOSITIONS FOR DETECTING PROTEIN MODIFICATIONS - Methods and compositions for detecting a protein modification in vitro and in vivo are disclosed. In certain embodiments, the protein modification detected is phosphorylation. | 03-28-2013 |
20130089882 | Chloroacetamidine Based Inhibitors and Activity Based Probes for the Protein Arginine Methytransferases - In accordance with certain embodiments of the present disclosure, a protein arginine methyltransferase inhibitor is provided. The inhibitor comprises an amino acid peptide joined to a chloroacetamidine warhead. | 04-11-2013 |
20130130291 | Labelling of Fusion Proteins with Synthetic Probes - The invention relates to new proteins called alkylcytosine transferases (ACTs) derived from O | 05-23-2013 |
20130137125 | CRYSTAL STRUCTURE OF HUMAN JAK3 KINASE DOMAIN COMPLEX AND BINDING POCKETS THEREOF - The present invention relates to human Janus Kinase 3 (JAK3) and JAK3-like binding pockets. The present invention provides a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. This invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention relates to methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to JAK3 protein or JAK3 protein homologues, or complexes thereof. The invention also relates to crystallizable compositions and crystals comprising JAK3 kinase domain and JAK3 kinase domain complexes with AMP-PNP. | 05-30-2013 |
20130143247 | VOLATILE ORGANIC COMPOUNDS FOR DETECTING CELL DYSPLASIA AND GENETIC ALTERATIONS ASSOCIATED WITH LUNG CANCER - The present invention provides methods of identifying a genetic abnormality such as mutation in EGFR or KRAS or ALK which is associated with the management of lung cancer or diagnosing, prognosing or monitoring the treatment of pre-cancerous conditions of the lung, such as bronchial dysplasia or atypical alveolar hyperplasia (AAH), through the detection of at least one volatile organic compound indicative of these states. | 06-06-2013 |
20130149729 | QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS - Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. | 06-13-2013 |
20130157299 | Tyrosine Kinome - Protein kinases are important signaling molecules involved in tumorigenesis. Mutational analysis of the human tyrosine kinase gene family (98 genes) identified somatic alterations in −20% of colorectal cancers, with the majority of mutations occurring in NTRK3, FES, GUCY2F and a previously uncharacterized tyrosine kinase gene called MCCK/MLK4. Most alterations were in conserved residues affecting key regions of the kinase domain. These data represent a paradigm for the unbiased analysis of signal transducing genes in cancer and provide useful targets for therapeutic intervention. | 06-20-2013 |
20130203095 | METHOD OF SCREENING PLACENTAL PROTEINS RESPONSIBLE FOR PATHOPHYSIOLOGY OF PREECLAMPSIA, AND MARKER FOR EARLY DIAGNOSIS AND PREDICTION OF PREECLAMPSIA - The present invention relates to a method of screening placental proteins responsible for pathophysiology of preeclampsia, and a marker for early diagnosis and prediction of preeclampsia. In accordance with one aspect of the present invention, there is provided a method of screening placental proteins responsible for pathophysiology of preeclampsia by 2D E-proteomics analysis, comprising: isolating placental proteins from a placental tissue; separating the isolated proteins two-dimensionally through 2D electrophoresis; and comparing and analyzing the separated proteins based on scanned gel images and differences in the images between normal placental proteins and preeclamptic placental proteins, wherein the comparison and analysis of the placental proteins based on the scanned gel images and differences in the images are accomplished by selecting proteins with differences of 140% or more between two placentas. | 08-08-2013 |
20130217055 | METHOD FOR PREDICTING TYROSINE KINASE INHIBITOR (TKI) RESISTANCE IN PATIENTS SUFFERING FROM CHRONIC MYELOGENOUS LEUKEMIA (CML) - The present invention relates to a method for determining or predicting the response of a patient diagnosed with chronic myelogenous leukaemia (CML) to treatment with a tyrosine kinase inhibitor. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles and inhibitions thereof thereby diagnosing CML patients resistant to treatment with Imatinib. | 08-22-2013 |
20130230874 | OPTICAL ANALYSIS METHOD USING MEASUREMENT OF LIGHT OF TWO OR MORE WAVELENGTH BANDS - There is provided an optical analysis technique enabling identification of a kind of light-emitting particle corresponding to a signal on a time series light intensity data or identification of a signal corresponding to light-emitting particles other than a particle to be observed in an optical measurement using a confocal microscope or a multiphoton microscope. The inventive optical analysis technique measures simultaneously and separately intensities of lights of two or more wavelength bands from a light detection region in a sample solution containing light-emitting particles of two or more kinds to generate time series light intensity data of the respective wavelength bands; detects signals simultaneously generated on the time series light intensity data of at least two wavelength bands; and identifies the simultaneously generated signals as signals of a light-emitting particle of at least one specific kind. | 09-05-2013 |
20130244262 | CARDIOMYOCYTE- AND/OR CARDIAC PROGENITOR CELL-PROLIFERATING AGENT AND METHOD FOR PROLIFERATING CARDIOMYOCYTES AND/OR CARDIAC PROGENITOR CELLS - The present invention provides a cardiomyocyte- and/or cardiac progenitor cell-proliferating agent comprising at least one compound selected from the group consisting of: a GSK3β inhibitor, ERK dephosphorylation inhibitor, Raf activator, CaMK2 inhibitor and p38 inhibitor; and a method for proliferating cardiomyocytes and/or cardiac progenitor cells using the agent. | 09-19-2013 |
20130244263 | METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 09-19-2013 |
20130316383 | METHODS OF MONITORING METABOLIC PATHWAYS - The present invention provides methods and compositions for monitoring cofactors and metabolites of a metabolic pathway of interest. The subject compositions and methods are particularly suited for monitoring the mevalonate pathway in a variety of cells. The invention also provides fermentation methods for the production of isoprenoids. | 11-28-2013 |
20130323766 | Production of Malonyl-CoA Derived Products Via Anaerobic Pathways - The present invention provides for novel metabolic pathways to convert biomass and other carbohydrate sources to malonyl-CoA derived products, such as hydrocarbons and other bioproducts, under anaerobic conditions and with the net production of ATP. More specifically, the invention provides for a recombinant microorganism comprising one or more native and/or heterologous enzymes that function in one or more engineered metabolic pathways to achieve conversion of a carbohydrate source to, e.g., long-chain hydrocarbons and hydrocarbon derivatives, wherein the one or more native and/or heterologous enzymes is activated, upregulated, downregulated, or deleted. The invention also provides for processes to convert biomass to malonyl-CoA derived products which comprise contacting a carbohydrate source with a recombinant microorganism of the invention. | 12-05-2013 |
20130323767 | Method to Identify Liver Toxicity Using Metabolite Profiles - The present disclosure relates to a methodology that identifies the underlying mechanisms that lead to hepatotoxicity. This is done by using the alterations in cellular metabolite profiles obtained before and after therapy/drug treatment in combination with a model of liver metabolism. Subsequently, by using a covariance matrix adaptation followed by evolutionary selection, it compares the drug-induced metabolite profiles obtained experimentally with those generated using the in silico model, automatically shortlists potential parameters whose alterations could have produced the drug-treated metabolite profile. Values of these parameters are estimated by formulating an optimal control problem to minimize the differences between the model-generated metabolite values and experimentally observed data. The estimated parameters are given as an input to the homeostatic liver model and simulations are carried out, thereby the results providing a mechanistic explanation for the development of toxicity. | 12-05-2013 |
20130330753 | 5-ALA FOR DETECTION OF BRAIN TUMORS - The present disclosure relates to methods for detecting brain tumors and assessing the recurrence of such tumors by administering a pharmaceutical composition comprising 5-aminolevulinic acid (5-ALA) and detecting the conversion of 5-ALA to protoporphyrin IX (PPIX) associated with brain-derived microparticles. | 12-12-2013 |
20140024061 | DETECTION OF LCAT ACTIVITY - The present disclosure relates to methods for detecting and measuring the activity of lecithin:cholesterol acyltransferase (LCAT) in solution (e.g. serum, plasma, cell culture media, aqueous solution) with fluorescent sterol substrates. The present disclosure also relates to a method for evaluating efficacy of a therapeutic agent for stimulating LCAT and for determining endogenous LCAT activity in a patient. Also disclosed are kits that are used to carry out the aforementioned methods and methods. | 01-23-2014 |
20140051104 | METHODS FOR PROTEIN PURIFICATION AND ANALYSIS - Methods to separate complex protein mixtures into individual proteins while maintaining protein function or enzyme activity are disclosed. They are designed to provide high resolution and efficient recovery of the functional proteins. The purified proteins may be analyzed with functional assays including enzymatic activities. | 02-20-2014 |
20140065650 | METHOD FOR THE REGULATION OF PROTEIN KINASE ACTIVITY IN VIVO AND IN VITRO - Disclosed herein is a substantially pure nucleic acid encoding a eukaryotic protein kinase having at least one mutated amino-acid residue located in its subdomain IX. Also disclosed is a substantially pure eukaryotic protein kinase polypeptide having at least one mutation in its subdomain IX, the kinase being encoded by the nucleic acid. | 03-06-2014 |
20140080161 | PHOSPHATASE COUPLED KINASE ASSAY - Assays and methods for detecting and quantifying the activity of a test kinase. The assay includes a nucleotide phosphatase at least ten times more active on ADP than on ATP and a free phosphate detector. The assay may also include a control kinase and/or ATP. Methods of the invention include combining a test kinase, a substrate of the test kinase, and a known quantity of ATP under conditions to produce ADP, combining the produced ADP with a phosphatase specific for ADP, and measuring free phosphate. The amount of phosphate produced directly correlates to the activity of the kinase.phosphatase coupled kinase assay | 03-20-2014 |
20140080162 | FLUORESCENCE LIFETIME EPIGENETICS ASSAYS - The invention is concerned with methods of assaying the activity of enzymes based on measurement of fluorescence lifetime (FLT). In particular, the invention relates to assays for enzymes which are capable of modifying the structure of peptide substrates, including for example enzymes catalysing methylation, demethylation, acetylation, deacetylation or deimination of peptide substrates. | 03-20-2014 |
20140080163 | LUMINESCENT PROBES HAVING A PHENANTHRIDINYL ANTENNA, AND METHODS OF USE - A molecular probe for the luminescent detection of nucleotides (e.g., adenosine nucleotides) is presented. In certain embodiments, the probe can readily distinguish between the three adenosine nucleotides in buffered aqueous conditions at neutral pH, a need for the direct monitoring of enzymatic reactions converting ATP to ADP or AMP. The probe is most efficient under millimolar concentrations of ATP, which are relevant to intracellular conditions. In preferred embodiments, the long luminescence lifetime of the probe readily enables time-gating experiments. | 03-20-2014 |
20140099655 | METHODS FOR ASSAYING ENZYME ACTIVITIES - The present invention provides compounds and methods for assaying activities of enzymes such as histone deacetylases and histone acetyltransferases. In some embodiments, the methods may be performed in one step. The compounds described herein features peptide-based compounds having at least one blocked lysine or arginine residue which are coupled to reporter moieties. The methods described herein involve reacting a compound described herein with an enzyme, such as a histone deacetylase enzyme or a histone acetyltransferase enzyme, and an endopeptidase that recognizes basic amino acids to release the reporter moiety which may be subsequently detected. | 04-10-2014 |
20140127730 | Method And System For Detecting Underlying Health Affections Using Biomarkers in Humans and Animals - The invention provides a method and system for developing and using diagnoses of one or more underlying health affections in humans or an animal specie using a plurality of biomarkers. A target one or more affections are defined and a set of biomarkers is selected. An index is computed based on the measured levels of the biomarkers. The biomarkers levels are discretized, and each discrete value is multiplied by a corresponding coefficient. The index scale is divided into ranges that are matched with health statuses. A subject's health affection status is subsequently determined by measuring the level of each biomarker in the set, computing the index and matching the index value to the predefined index scale. | 05-08-2014 |
20140127731 | Method And System For Detecting and Differentiating Cancer and Sepsis in Mammals Using Biomarkers - The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using Thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale. | 05-08-2014 |
20140141461 | METHODS FOR IMPROVING AND MANAGING NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITION BASED TREATMENT - A transformed yeast cell includes: a nucleic acid sequence coding for a reverse transcriptase; a reverse transcription indicator; a nucleic acid sequence coding for deoxycytidine kinase (dCK); and at least one nucleic acid sequence coding for nucleoside transporter. Methods for screening a compound with the ability to inhibit reverse transcription and for predicting the sensitivity of a reverse transcriptase to a NRTI compound, particularly a reverse transcriptase derived from a virus infecting a subject using the transformed Yeast cell are also described. | 05-22-2014 |
20140154720 | PLANT DIACYLGLYCEROL ACYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a diacylglycerol acyltransferase. The invention also relates to the construction of a chimeric gene encoding all or a portion of the diacylglycerol acyltransferase, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the diacylglycerol acyltransferase in a transformed host cell. | 06-05-2014 |
20140162298 | IMMOBILIZED ENZYMATIC REACTOR - An immobilized enzymatic reactor can include a wall defining a chamber having an inlet and an outlet; a solid stationary phase covalently linked to an enzyme and disposed within the chamber; and a pressure modulator in fluid communication with the chamber and adapted to support continuous flow of a liquid sample comprising a polymer analyte through the inlet, over the solid stationary phase, and out of the outlet under a pressure between about 2,500 and 35,000 psi. In one example, the solid stationary phase includes inorganic/organic hybrid particles in an ultra performance liquid chromatography system, the enzyme is a protease, and the polymer analyte is a polypeptide. The immobilized enzymatic reactor can prepare an analyte for applications such as for hydrogen deuterium exchange mass spectrometry. | 06-12-2014 |
20140178910 | METHOD FOR ASCERTAINING THE ISCHEMIC LEVEL OF A PATIENT WITH SUSPECTED STROKE - A method for determining the ischemic levels of suspected stroke patients comprises the following steps:
| 06-26-2014 |
20140178911 | CHARACTERIZATION OF THERMOSTABLE DNA POLYMERASE - Methods detecting covalent lysine modifications in DNA polymerases are provided. These methods are particularly useful in determining the extent and location of a lysine modification in a DNA polymerase. | 06-26-2014 |
20140212904 | Fluorescence Assay For Ghrelin O-Acyltransferase Activity - An assay to detect ghrelin O-acyltransferase activity using an acrylodan-labeled peptide mimic of ghrelin that provides for high-throughput screening for ghrelin O-acyltransferase inhibitors and detection via high performance liquid chromatography. Alternatively, the assay for ghrelin acylation may be based on a synthetic peptide substrate that mimics the N-terminal sequence of ghrelin and has an environmentally-sensitive fluorophore attached to its C-terminal amino acid through chemoselective ligation. | 07-31-2014 |
20140220609 | SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA - Methods, processes, systems, and apparatuses are disclosed for predicting minoxidil response in the treatment of androgenetic alopecia based on colorimetric assay for sulfotransferase activity. In particular, SULT1A1 activity may be used as an indicator of minoxidil response. A genetic test for alleles of the SULT1A1 gene may be performed to provide a more personalized therapy. | 08-07-2014 |
20140234881 | LATERAL FLOW AND FLOW-THROUGH BIOASSAY DEVICES BASED ON PATTERNED POROUS MEDIA, METHODS OF MAKING SAME, AND METHODS OF USING SAME - Embodiments of the invention provide lateral flow and flow-through bioassay devices based on patterned porous media, methods of making same, and methods of using same. Under one aspect, an assay device includes a porous, hydrophilic medium; a fluid impervious barrier comprising polymerized photoresist, the barrier substantially permeating the thickness of the porous, hydrophilic medium and defining a boundary of an assay region within the porous, hydrophilic medium; and an assay reagent in the assay region. | 08-21-2014 |
20140234882 | Oxygenase-Based Biosensing Systems For Measurement Of Halogenated Alkene Concentrations - A biosensing system that measures the concentration of halogenated alkenes is disclosed. | 08-21-2014 |
20140273044 | METHOD FOR REPLACING BIOMARKERS OF PROTEIN KINETICS FROM TISSUE SAMPLES BY BIOMARKERS OF PROTEIN KINETICS FROM BODY FLUIDS AFTER ISOTOPIC LABELING IN VIVO - Provided herein are method for measuring the rate of synthesis, breakdown, transport, or other kinetic parameters of a protein in a tissue of medical interest, without requiring physical sampling of the tissue, by a measurement of the protein in a body fluid. Methods may include selecting one or more target proteins in a tissue; administering an isotope-labeled molecule to a subject for a period of time sufficient for said isotope-labeled molecule to enter into and label the one or more target proteins to produce one or more isotope-labeled target proteins; collecting a volume of a body fluid, wherein the volume comprises one or more isotope-labeled target proteins that escaped or were released from the tissue; enriching or isolating the one or more isotope-labeled target proteins from the volume; performing a mass spectrometric measurement of the isotopic content, rate of incorporation, and/or pattern or rate of change in isotopic content and/or pattern of isotope labeling of the one or more enriched or isolated isotope-labeled target proteins; and calculating at least one kinetic parameter of the one or more enriched or isolated isotope-labeled target proteins, where the kinetic parameter of the one or more isotope-labeled target proteins from the volume of a body fluid reflects the corresponding kinetic parameter of the one or more target proteins in the tissue; and inferring the at least one kinetic parameter of the one or more target proteins in the tissue based on the corresponding at least one kinetic parameter of the one or more target proteins in the body fluid. | 09-18-2014 |
20140273045 | Modular Biochemical Signaling Laboratory Breadboard for Disease Research, Drug Discovery, Cell Biology, and Other Applications - A “breadboard” approach by which a biochemical signaling process, pathway, or network under study is separated or segmented into interconnected smaller portions, at least one of which can to a degree of approximation be accurately emulated with a replica microscale and/or nanoscale fluidic implementation whose constituent species can be closely controlled and at least one aspect of whose behavior can be measured. Control and measurement information interfaces with a computer that executes algorithms comprising one or more of a control process, control event-script, experiment, data recording, and mathematical model. A model can be used to simulate the actions, behavior, or other aspects of another portion of the biochemical signaling process, pathway, or network. Replica constituents can include enzymes, other proteins, lipids, ions, peptides, and other materials provided under controlled conditions and timing, as well as varying degrees of competitive species, drugs, environmental influences, and substitute or representative molecular crowding. | 09-18-2014 |
20140287446 | Monoclonal Antibody For Acetylamantadine - A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine. | 09-25-2014 |
20140287447 | Ultrasensitive methodology for quantifying the kinase catalytic activity of any protein kinase in biological/clinical samples or recombinant/purified proteins using near-infrared-fluorescence (NIRF)-labeled, kinase-selective peptide substrates and a combination of kinase-selective inhibitors to define individual kinase activity - A non-radioactive, ultrasensitive methodology for the quantification of protein kinase catalytic activity of any protein kinase in, for example, biological/clinical samples or recombinant/purified proteins, based on using near-infrared-fluorescence (NIRF)-labeled peptide substrates that are selective for individual protein kinases and using a combination of kinase-selective inhibitors to define the catalytic activity of individual protein kinases, including but not limited to, a substrate for phosphorylation by a protein kinase comprising a core peptide having the formula: (N-terminus)-Arginine-Lysine-Arginine-Serine-Arginine-Lysine-Glutamic-acid-(C-terminus); and an indicator component covalently bonded to the core peptide. | 09-25-2014 |
20140308691 | METHOD FOR THE DETERMINATION OF THE CONCENTRATION OF VITAMIN B6 IN A SAMPLE - The invention relates to methods for the determination of vitamin B6 in samples as well as to reagent compositions for assaying a sample for vitamin B6 and to a test kit suitable for carrying out the methods according to the present invention. Further, the invention relates to the use of such methods for the application to different analyzing devices such as micro-titer plate readers and fully automated clinical chemistry analyzers (autoanalyzers). | 10-16-2014 |
20140315229 | TESTING SYSTEM ARRANGEMENT AND METHOD FOR TESTING - This invention relates to a testing system arrangement for assessing the level of a biochemical marker, comprising a disposable device ( | 10-23-2014 |
20140329259 | Systems and Methods of Sample Processing and Fluid Control in a Fluidic System - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. | 11-06-2014 |
20140329260 | METHOD OF DIAGNOSIS OF FIBROTIC DISEASES - The present invention relates to a new diagnosis method in the field of hepatology, combining measurement of serum markers and of liver elasticity. | 11-06-2014 |
20140329261 | TREATMENT OF CANCER BY INHIBITION OF THE MYD88/ERK MAP KINASE INTERACTION - A method for selecting in vitro compounds is capable of potentiating the effect of a DNA damage inducing chemotherapy agent for the treatment of cancer, and includes selecting compounds inhibiting the interaction between MyD88 and ERK MAP KINASE. | 11-06-2014 |
20140335550 | FLUORESCENT SUBSTRATES FOR DETERMINING LYSINE MODIFYING ENZYME ACTIVITY - The invention relates to a compound of Formula I: | 11-13-2014 |
20140335551 | SULFOTRANSFERASE ASSAY - A method of detecting sulfotransferase activity including conducting a first reaction comprising, measuring free phosphate produced by the first reaction, and comparing the measured free phosphate to a free phosphate standard curve or equation or to a free phosphate level obtained in a separate reaction. The first reaction includes combining the sulfotransferase, Golgi-resident PAP-phosphatase (gPAPP), a 5′-nucleotidase, a substrate of the sulfotransferase, and 3′-phosphoadenosine-5′-phosphosulfate (PAPS) under conditions to produce 3′-phosphoadenosine-5′-phosphate (PAP). | 11-13-2014 |
20140335552 | METHOD AND APPARATUS FOR DETECTING CANCER IN MAMMALS - The invention provides a method and apparatus for detecting cancer using the measurement of acute-phase proteins (APPs) and the measurement of thymidine kinase activiy level in body fluids. An index is calculated based on the measured data and compared with a pre-established reference that allows a pratitioner to determine a high probabilty that a patient is a carrier of cancer. | 11-13-2014 |
20140342383 | ELECTROCHEMICAL ASSAY FOR THE DETECTION OF ENZYMES - The invention relates to novel compositions and methods for the detection of enzymes using the nuclear reorganization energy, λ, of an electron transfer process. | 11-20-2014 |
20150031061 | COMPOSITIONS AND METHODS RELATING TO FUSION PROTEIN BIOMARKERS - The present invention provides fusion proteins as biomarkers specific for chromosomal translocation-based conditions (e.g., cancer), related methods for detecting fusion protein biomarkers associated with chromosomal translocation-based conditions, related methods for quantifying amount of fusion protein expression, and related methods for diagnosing chromosomal translocation-based conditions through detection of such fusion protein biomarkers. Such fusion protein biomarkers and related methods additionally find use in research settings. | 01-29-2015 |
20150044712 | METHOD AND KIT FOR ANALYZING PROTEIN-PROTEIN INTERACTION USING NANOCLUSTER FORMATION - For efficient analysis of a protein-protein interaction, the present disclosure provides a kit for analyzing a protein-protein interaction, the kit including: a 1 | 02-12-2015 |
20150044713 | METHOD - The present invention provides a method of quantifying the activity of a protein modifying enzyme in a sample, comprising: (i) grouping modified peptides from a first sample and modified peptides from a second sample into a single group according to one of the following parameters: (a) modified peptides having a modification site that is modified by the same protein modifying enzyme; or (b) modified peptides having a modification site that is part of the same modification motif; (ii) calculating enrichment of the modified peptides from the first sample compared to the modified peptides from the second sample in the group; and (iii) calculating the statistical significance of said enrichment; wherein a statistically significant enrichment is indicative of a protein modifying enzyme being activated in the first sample compared to the second sample. In some embodiments, the method further comprises identifying modified peptides in a first sample and a second sample using mass spectrometry (MS) prior to step (i). | 02-12-2015 |
20150079617 | METHOD FOR DETERMINING BIOCHEMICAL PARAMETERS OF A BODY FLUID - The invention relates to a method for determining biochemical parameters of a body fluid, wherein a sample of said body fluid in the form of a droplet is transported through a channel of a microfluidic system using a carrier liquid, mixed with a reagent thus initiating a chemical reaction between the sample and the reagent, and the result of the chemical reaction is measured, preferably with a spectrophotometer, whereby the said biochemical parameters of the body fluid are determined, characterised in that the material used for fabrication of the microfluidic system and the said carrier liquid is pair of Teflon and Fluorinert HFE-7100. | 03-19-2015 |
20150079618 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS - The present invention provides moenomycin-based probe compounds of Formula (I) for use in screening inhibitors of bacterial glycosyltransferases. The present invention also provides bacterial glycosyltransferase screening assays using compounds of Formula (I). | 03-19-2015 |
20150087002 | METHODS AND KITS FOR DETECTION OF O-GLCNAC AND N-GLCNAC MODIFICATION OF PEPTIDES AND PROTEINS - Methods and kits for detecting the presence of GlcNAc modification of a peptide or protein. The steps of detection may include combining the peptide or protein with PAP | 03-26-2015 |
20150093771 | MICROFLUIDIC ANALYTICAL DEVICE FOR ANALYSIS OF CHEMICAL OR BIOLOGICAL SAMPLES, METHOD AND SYSTEM THEREOF - An analytical device for analysis of chemical or biological samples, a method of using such a device, based on rotation of the device, integrated sample dosing and optical detection, and a system comprising such a device are disclosed. The analytical device comprises a device body having a liquid processing unit. The liquid processing unit comprises a mixing chamber for mixing a sample with a reagent, a sample dosing chamber for delivering a defined volume of the sample to the mixing chamber, and a reagent channel for delivering the reagent to be mixed with the sample, wherein the mixing chamber also serves as a detection chamber. | 04-02-2015 |
20150132783 | Neuroprotective Chemicals and Methods for Identifying and Using Same - Provided herein are methods for identifying a compound having cell-protective (e.g., neuroprotective) activity. Compounds identified therefrom are also provided. These compounds can be used to treat various diseases, disorders, or conditions associated with, for example, unwanted cell death. | 05-14-2015 |
20150140585 | GAS BIOSENSORS - Microbial biosensors that generate gas outputs in hard-to-image materials using exogenous methyl halide transferase (MHT) genes. By varying the promoter that is fused to the MHT gene, biosensors for different triggers can be made. | 05-21-2015 |
20150344933 | BIOMARKERS FOR RAPID DETECTION OF AN OCCURRENCE OF A STROKE EVENT - A diagnostic assay for detecting an occurrence of a stroke event in a mammalian subject. The assay comprises the steps of: (i) separating a plasma fraction from a blood sample collected from the mammalian subject; (ii) quantifying in the plasma fraction a L-glutamine hydroxylamine glutamyl transferase (L-GHGT) activity; (iii) quantifying in the plasma fraction a gamma glutamyl hydroxamate synthetase (GGHS) activity; (iv) adding together or alternatively calculating the combinatorial probability for the quantified L-GHGT activity and the quantified GGHS activity to produce a value for the net glutamine synthetase activity, and (v) correlating the net glutamine synthetase activity value with net glutamine synthetase activity values from healthy subjects to detect an occurrence of a stroke event in the mammalian subject. Also disclosed are kits comprising reagents and instructions for performing a diagnostic assay to detect and quantify L-GHGT activity and/or GGHS activity. | 12-03-2015 |
20150344934 | Novel High Throughput Assay for finding new Jak3 Interacting Compounds, Biomolecules, and Inhibitors. - Janus Kinase 3 is a non-receptor tyrosine kinase that mediates signals initiated by cytokines through interactions with the receptors of cytokines. Abnormal activation of Jak3 was associated with human hematologic and epithelial malignancies. Inhibitors of Jak3 have shown utility in many different disease such as autoimmune disorders, allograft rejection during transplantation, acute lymphoblastic leukemia, Type 1 diabetes, rheumatoid arthritis and allergy and asthma. Since these inhibitors make their way into clinical trials with profound effects, it is essential to develop a sensitive, precise, and rugged screening tool to screen synthetic compounds or other biomolecules that has the potential to modulate Jak3 functions and hence treat a wide variety of diseases. Present invention relates to novel high throughput system for finding previously unknown Jak3 interacting compounds, human biomolecule (e.g. proteins or others), and those compounds that can inhibit Jak3 activations. All these identified compounds and molecules can be used for the treatment of a wide variety of diseases (listed in table 1) where Jak3 activations or its interactions with other biomolecules are essential for disease sustenance or propagation in human body. | 12-03-2015 |
20150346219 | METHODS OF DETERMINING LEVELS OF FREE AMINO ACIDS AND DIPEPTIDES AND DIAGNOSING ALZHEIMER'S DISEASE - Provided herein are methods of diagnosing Alzheimer's disease (“AD”) based on characteristic changes of the levels of certain free amino acids or dipeptides (collectively termed as “AD diagnosis markers”) in the body fluid sample of an individual, carnosine synthesis activities in the plasma, and dopamine synthesis activities in the plasma. Also provided are methods of simultaneously determining the levels of at least two free amino acids or dipeptides in the biological fluid sample of an individual. | 12-03-2015 |
20150376679 | METHODS FOR ANALYZING GLYCAN-DERIVED MONOSACCHARIDES - The present disclosure provides a method for analyzing glycan-derived monosaccharides in a sample. The present disclosure also provides a method for detecting or monitoring a disease or disorder in a patient. In addition, the present disclosure provides a method of determining aberrant glycotransferase activity. The present disclosure further provides a system for analyzing or comparing glycates in a sample. | 12-31-2015 |
20160002611 | Methods and Apparatus for Cell-Free Microfluidic-Assisted Biosynthesis - A trans-disciplinary system for cell-free biosynthesis includes a cell-free transcription-translation (TX-TL) tool and modular, generalizable microfluidic architectures. Both components of the system are independently functional and are combinable into a cell-free biosynthesis platform. In the first component, modular plasmid libraries are used to program bacterial cell-free TX-TL systems. Each plasmid holds one gene or operon, and all the genes are controlled by the same promoter, so that the stoichiometry of enzyme synthesis is determined by the stoichiometry of plasmids in the reaction. In the second part, in order to facilitate high throughput mixing and matching of gene units from the modular plasmid libraries, a modular, reconfigurable, flexible, and scalable microfluidic architecture is employed. The microfluidic modules share common form factors and port/valve locations, so that a small set of module types, with multiple instances of each type interconnected in different geometries, allows simple reconfiguration to achieve different modes of operation. | 01-07-2016 |
20160047740 | SAMPLE TEST METHOD, MICROFLUIDIC DEVICE, AND TEST DEVICE - A sample test method, microfluidic device, and test device efficiently and accurately compensates for interference of an interfering substance present in a sample using optical measurement without addition of a separate reagent for detecting the interfering substance. The sample test method includes: measuring an optical characteristic value of a target substance present in a sample; measuring an optical characteristic value of an interfering substance present in the sample; and determining a concentration of the target substance for which interference of the interfering substance is compensated for based on the optical characteristic value of the interfering substance. | 02-18-2016 |
20160075993 | MEDIUM FOR CULTURING STEM CELLS - Culture media, which contain albumin carrying a reduced amount of fatty acid, are useful for culturing stem cells. | 03-17-2016 |
20160090618 | CHARACTERIZATION OF THERMOSTABLE DNA POLYMERASE - Methods detecting covalent lysine modifications in DNA polymerases are provided. These methods are particularly useful in determining the extent and location of a lysine modification in a DNA polymerase. | 03-31-2016 |
20160097083 | SCREENING ASSAY FOR IDENTIFICATION OF POLY(ADP-RIBOSE) POLYMERASE 1 INHIBITORS - Screening methods as well as systems and kits for identifying inhibitors of DNA-independent, histone H4-dependent activation of PARP-1 are provided. The methods comprise screening molecules for their capacity to inhibit the activation and/or biologic activity of PARP-1, as measured by poly(ADP)-ribose production from nicotinamide adenine dinucleotide. PARP-1 inhibitors identified through the screening methods may be used to treat cancer in which PARP-1 activation or biologic activity plays a role. | 04-07-2016 |
20160116455 | FLUORESCENT PROBE SENSING TYROSINE KINASE AND USE THEREOF - A fluorescent probe for detecting a tyrosine kinase using a compound having an ortho-hydroxy-benzaldehyde structure, and use thereof are provided. The fluorescent probe can show a change in fluorescence when the compound binds with a tyrosine kinase. The compound can be readily synthesized and has high stability and low cytotoxicity in vivo. The fluorescent probe can be used to image cells or tissues overexpressing the tyrosine kinase, the fluorescent probe can be effectively used in a composition for imaging the tissues and a method of imaging the tissues. Also, the fluorescent probe can be used to image cancer cells or tissues since the fluorescent probe can exhibit fluorescence when the fluorescent probe binds to the cancer cells or tissues overexpressing the tyrosine kinase. | 04-28-2016 |
20160123957 | Visualization of P-TEFb by Fluorescence Complementation - Provided herein is a novel assay for the quantification of P-TEFb activation in living cells. The invention, in one embodiment, comprises cells which express P-TEFb and a P-TEFb-phosphorylated or P-TEFb-binding species, for example the C terminal domain of RNA polymerase II. Each of the P-TEFb and P-TEFb-phosphorylated or P-TEFb-binding species comprises a complementary signal moiety, for example complementary fragments of a fluorescent protein, such that when the P-TEFb interacts with the P-TEFb-phosphorylated or P-TEFb-binding species, the signal moieties are in sufficiently close proximity to generate a detectable signal. | 05-05-2016 |
20160138078 | MODULATORS FOR SIRT6 AND ASSAYS FOR SCREENING SAME - Method for identifying a modulator of Sirt6, PfSir2a, or Sirt7 deacylase activity, wherein a fatty-acylated substrate containing an acyl-lysine moiety and an indicator moiety is contacted with Sirt6, PfSir2a, or Sirt7 in the presence of a candidate compound under conditions for Sirt6, PfSir2a, or Sirt7 to deacylate the substrate, wherein the acyl is a hydrophobic fatty acyl group containing a hydrocarbon group having at least three carbon atoms connected by carbon-carbon bonds; contacting the deacylated substrate with a cleavage agent that cleaves the linkage between the lysine and indicator moiety to generate a detectable signal; and correlating a quantified Sirt6, PfSir2a, or Sirt7 deacylase activity therefrom. Modulating compounds of Sirt6, PfSir2a, or Sirt7 deacylase activity are also described, as are pharmaceutical compositions thereof, methods of treatment by administration of the modulating compounds, and kits for practicing the method. | 05-19-2016 |
20160146816 | TUMOR ENERGY METABOLISM PROFILING - A diagnostic method for the prediction of tumor prognosis including the likelihood of formation of metastases or of relapse or local recurrence in tumor related diseases in a mammal and the provision of a therapy recommendation for a patient the enzyme activity of key enzymes of the energy metabolism is determined in fresh tumor tissue or fresh tumor cell mass after 24 hours incubation in a cell culture medium. Incubation reduces nutrition, drug and biopsy/surgery effects on the energy metabolism of the tissue slices or the cell mass. The quotients of enzyme activity of anaerobic enzymes are put in ratio to the enzyme activity of aerobic enzymes or vice versa. Said ratio can be taken into account for prognosis of metastasis and a therapy recommendation. | 05-26-2016 |
20160160264 | DIAGNOSTIC IN VITRO METHOD - Disclosed is a diagnostic in vitro method for determining the activity of thiopurine S-methyltransferase (TPMT) in individuals to be examined, characterized in that the content of urothione and/or jukathione in body fluids is determined. | 06-09-2016 |
20160194683 | Gas Biosensors | 07-07-2016 |
20160201031 | COMPOSITION AND METHODS FOR CULTURING CELLS | 07-14-2016 |
20160201111 | Method and Apparatus for Measuring Protein Post-Translational Modification | 07-14-2016 |
20170233788 | Cysteine Labelling | 08-17-2017 |